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ABSTRACT 
 
 
Background:  Prolonged ischaemia time during autogenous free muscle 
transfer, can lead to ischaemia reperfusion (I/R) injury and local necrosis of the 
muscle.  It has been demonstrated that the phenomenon of ischaemic 
preconditioning (IPC) confers biphasic infarct protection in a porcine skeletal 
muscle flap model.  Further to this, the hybrid nitrovasodilator and KATP channel 
opener Nicorandil, is known to induce 24h uninterrupted infarct protection in 
myocardial models.  We therefore hypothesised that Nicorandil could 
pharmacologically confer late-phase infarct protection of skeletal muscle from 
I/R injury. 
Methods:  Yorkshire pigs (mean 17.9kg) with bilateral 8x13cm Latissimus 
Dorsi (LD) muscle flaps, received i.v. Nicorandil (3mg/kg) before being 
subjected to 4h ischaemia followed by 48h reperfusion.  
Results:  Nicorandil induced late-phase preconditioning appeared at 24h after 
Nicorandil injection and lasted for 72h before waning.  LD infarction rates were 
reduced to 22+/-2, 25+/-2 and 28+/-2% at 24h, 48h and 72h respectively, 
compared to the ischaemic control of 40+/-2%.  Further to this, Nicorandil 
preconditioning was associated with a reduction in mitochondrial free calcium 
content, preservation of muscle ATP content and attenuation of neutrophilic 
myeloperoxidase activity during the first hour of reperfusion.  Injection with the 
specific sarcolemmal KATP (sKATP) inhibitor HMR-1098 or non-specific KATP 
inhibitor Glibenclamide before Nicorandil injection completely blocked the 
infarct-protective effects.  Injection of the specific mitochondrial KATP (mKATP) 
inhibitor 5-HD or Glibenclamide before the onset of reperfusion also abolished 
Nicorandil preconditioning. 
 3 
Conclusion:  These findings support the hypothesis that a single dose of 
Nicorandil induces 48h of uninterrupted late-phase infarct protection in skeletal 
muscle.  Further to this, sKATP and mKATP channels play a central role in the 
trigger and mediator mechanisms, respectively.  Nicorandil is a potential new 
therapy to augment the ischaemic tolerance of skeletal muscle for patients 
undergoing autogenous free muscle transfer or composite tissue 
allotransplantation. 
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1.0 INTRODUCTION 
 
1.1 History & The Clinical Problem 
 
The specialty of Plastic and Reconstructive Surgery involves the use of tissue 
flaps to reconstruct form or function following trauma, oncological disease or 
congenital abnormality.  The first half of the twentieth century saw the 
development of local and tubed-pedicled skin flaps in reconstructive challenges.  
These flaps were classed as ‘random pattern flaps’ and were therefore limited by 
their length to breadth ratio to prevent distal tip necrosis.  At this time the 
vascular anatomy of the skin and fascia were not fully understood and therefore 
vascular patterns were not adhered to.  The advent of ‘axial pattern flaps’ in the 
1970s was in fact based on much earlier work by Salmon (Salmon et al. 1936).  
Their advantageous length-to-breadth ratios expanded the repertoire of plastic 
surgeons, enabling them to reconstruct more complex defects with fewer 
operations.  It was not until Ger described the use of pedicled muscle flaps in 
lower leg trauma (Ger 1972) that advances in the knowledge of vascular muscle 
anatomy became apparent.  It was soon realised that a skin paddle could be 
carried on a vascularised muscle pedicle, thereby improving the range of 
composite tissue used in reconstructive flap options.  Mathes and Nahai provided 
the first definitive description of the muculocutaneous system of flaps and 
classified the different vascular anatomical axes (Mathes et al. 1981). 
 
The ‘free flap’ was first introduced by Ian Taylor and colleagues in Melbourne, 
Australia 1973 (Daniel et al. 1973).  They described the autogenous free transfer 
of a groin flap for wound coverage of a foot defect.  The term was modified to 
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‘free tissue transfer’ to indicate that a wide range of tissues, such as skin, muscle 
and/or bone, could be isolated on their vascular supply and transplanted to 
distant sites in the body as a single-stage procedure.  This discovery, spurred on 
by improvements in loupe magnification, micro-instruments and suture 
materials, became an important part of a plastic surgeon’s armamentarium.  Free 
tissue transfer is now used in the reconstruction and restoration of form, such as 
in breast reconstruction after mastectomy; and restoration of function, such as in 
facial paralysis surgery and in Volkmann’s ischaemic contracture. 
 
Along with this evolution in flap reconstruction, new issues have surfaced 
regarding the vascular supply to the flap.  Free tissue transfer requires division of 
the vascular pedicle supplying, for example, a muscle / musculocutaneous flap, 
followed by an obligatory period of warm ischaemia prior to microsurgical 
anastomosis. There are circumstances when the restoration of the muscle flap 
circulation is delayed, such as a difficult and time-consuming anastomosis, 
perioperative vasospasm and thrombosis or external pedicle compression. This 
can result in a prolonged warm ischaemia time, which if left unmanaged, will 
eventually lead to lethal ischaemic insult and subsequent tissue necrosis. This 
culminates in failure of the free tissue transfer. 
 
Further to this, prolonged tissue ischaemia and subsequent reperfusion injury can 
occur in other surgical scenarios, such as a protracted limb tourniquet time 
during orthopaedic / vascular procedures to provide a bloodless operative field; 
clamp control of major vessels during vascular bypass surgery; and limb 
replantation following traumatic amputation.  
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Despite the advances in surgical technology and the increased experience in 
specialist centres, the overall failure rate of free tissue transfer remains around 
5% (Khouri 1992; Khouri et al. 1998).  This is a significant clinical problem, as a 
flap failure constitutes a failure of the reconstruction of the patient’s defect, 
necessitating further surgical procedures and exploration of alternative options.  
These additional procedures result in a prolonged hospital stay and add to the 
psychological morbidity of the patient. 
 
The aetiology of free flap failure appears to be multifactorial, however it is 
believed that the incidence could be further reduced by the discovery of an 
effective treatment for the prevention of ischaemia reperfusion tissue injury, 
caused by a prolonged ischaemic insult followed by subsequent reperfusion of 
the tissues. 
 
 
 
1.2 Ischaemia Reperfusion Injury in Musculoskeletal Reconstructive 
Surgery 
 
Various tissues are commonly exposed to periods of warm ischaemia in both 
elective and traumatic surgical scenarios. The tolerance of a tissue for ischaemia 
depends on tissue type as well as its volume, metabolic activity and temperature.  
It is no surprise that skeletal muscle, with its high metabolic activity has the 
lowest tolerance to ischaemia (Blaisdell 2002) (Figure 1).  This is due to the fact 
it comprises the vast majority of a limb’s weight, blood-flow and therefore 
energy demands.  However, these values are estimates as it is difficult to tell 
 20 
when muscle has died.  Macroscopic and even microscopic changes in the 
skeletal muscle cells do not become apparent for many hours following muscle 
death.  Belkin et al went some way to quantifying this critical ischaemic interval 
by using spectrophotometric tetrazolium analysis of rat skeletal muscle to show 
that significant muscle damage occurred after 3 hours of ischaemia (Belkin et al. 
1988).  Eckert et al further reformed this level using nuclear magnetic resonance 
(NMR) spectroscopy, stating that in fact normo-thermic human skeletal muscle 
has a critical ischaemic tolerance of only 2 hours 15 minutes (Eckert et al. 1991).  
This critical ischaemia time was estimated by determining the point at which the 
Adenosine Triphosphate (ATP) pool was depleted; and is heavily dependent on 
muscle temperature (Eckert et al. 1991). 
 
 
 
Tissue Time 
• Muscle 
• Nerve 
• Fat 
• Skin 
• Bone 
• 4 hours  
• 8 hours 
• 13 hours 
• 24 hours 
• 4 days 
 
Figure 1.1.  Critical tissue ischaemia time estimates based on assessment of 
absolute ischaemia induced prior to replantation (Blaisdell 2002). 
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1.2.1 Skeletal Muscle Metabolism & Morphology 
 
Normal physiological conditions in the skeletal myocyte involve oxidative 
phosphorylation of fatty acids, ketone bodies and phosphates to produce 
Adenosine Triphosphate (ATP), the cell’s main energy supply.  Phosphocreatine 
is an energy-rich phosphate compound found in high concentrations in the cell 
under these aerobic conditions. Phosphocreatine is tied to ATP by the enzyme 
creatine kinase and thus the ATP pool is consistently being replenished by the 
phosphocreatine reserve. 
 
Under anaerobic conditions, as well as the phosphocreatine reserve, the cell 
continues to synthesize ATP by glycolysis and purine nucleotide deamination.  
With glycogen stores abundant in skeletal muscle, anaerobic glycolysis 
continues to produce ATP until it is inhibited by lactic acidosis (Walker 1986; 
Lindsay et al. 1990). 
 
Much of the debate in the past has been regarding the point at which irreversible 
damage occurs in the myocyte, resulting in cell necrosis.  Lindsay demonstrated 
a sustained level of muscle ATP content in up to 3 hours ischaemia in canine 
gracilis muscle (Lindsay et al. 1990) predominantly due to depletion of creatine 
phosphate stores. Only when the phosphocreatine pool has been exhausted, do 
we get a decline in the muscle ATP stores, known as Bendall’s delay phase 
(Bendall 1973).  This will eventually result in ATP depletion and cell death.  
During this interim phase, reperfusion of the muscle and restoration of oxidative 
phosphorylation can replenish ATP as long as the mitochondria are functioning 
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normally and there is availability of suitable substrates in the cell (Walker 1986).  
It is important to note that the rate of breakdown of ATP and phosphocreatine in 
the ischaemic myocyte is highly dependant on not only temperature, but species 
and fibre type as well.   
 
Type 1 fibres are slow twitch muscle fibres more suited to endurance work and 
therefore more resistant to fatigue.  They are the predominant fibre type in the 
postural muscles of the body.  They have the highest oxidative capacity and the 
highest lipid stores, but in contrast, have the lowest glycogen stores and therefore 
a reduced amount of glycolytic enzyme capacity.  Type 2 fibres, on the other 
hand, are fast twitch fibres found predominantly in limb musculature, like 
gastrocnemius and the hamstring muscles.  They are sub-divided into 2a and 2b 
with increasing amounts of glycolytic capacity to provide energy by anaerobic 
metabolism.  Intuitively, Type 1 fibres have predominantly oxidative metabolism 
of lipid stores as their energy source and are therefore much more vulnerable to 
hypoxia than Type 2 fibres (Lindsay et al. 1990; Blaisdell 2002).  
 
 
1.2.2 Early Concepts of Reperfusion Injury 
 
In autogenous free muscle transfer, a relatively small volume of skeletal muscle 
may be subject to reperfusion injury, causing a local inflammatory response with 
tissue hyperaemia and oedema related to the release of muscle breakdown 
products such as histamine, lactate, lysozomes, myoglobin and various 
proteolytic enzymes (Steinau 1988).  These breakdown products not only trigger 
the inflammatory response but are also prothrombotic and therefore activate the 
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intrinsic clotting pathway, resulting in aggravation of pre-existing microvascular 
damage (Eckert et al. 1991; Blaisdell 2002). 
 
If the volume of muscle involved is greater, for example, following extremity 
replantation or in a compartment syndrome, muscle necrosis with subsequent 
reperfusion can cause serious systemic complications affecting distant organs. 
This can result in life threatening metabolic consequences such as acidosis, 
hyperkalaemia and myoglobinuria (Walker 1986; Blaisdell 2002). This was first 
alluded to by the work of Bywaters in World War II, who noted the brown 
pigment of myoglobin in the urine of casualties that died of renal failure 
following crush injuries to the extremities (Bywaters et al. 1941).  Haimovici et 
al clarified the association of these systemic metabolic changes with arterial 
reperfusion and later coined the term ‘myonephropathic-metabolic syndrome’ 
(Haimovici 1960).  Further distant organ damage is apparent in the form of lung 
dysfunction, caused by the release of ROS and cytokines, resulting in diffuse 
capillary leakage and ultimately non-cardiogenic pulmonary oedema (Khalil et 
al. 2006).  These catastrophic changes following replantation of a leg or arm, 
have resulted in re-amputation to avoid a potentially fatal outcome (McCutcheon 
et al. 2002). 
 
By the late 1960s, the connection had been made between prolonged tissue 
ischaemia and subsequent reperfusion injury causing local necrosis and systemic 
metabolic sequelae.  This trio of metabolic acidosis, hypotension and 
myoglobinuria had been termed ‘de-clamping shock’ (Vetto et al. 1968) 
referring to the flushing out of toxic metabolites following the release of vascular 
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clamps and reperfusion of a limb.    However, little was known about the 
pathophysiology of ischaemia reperfusion injury. 
 
 
1.2.3 Acute Ischaemia Reperfusion Injury 
 
Reestablishment of blood flow to previously ischaemic tissues, resulting in local 
/ systemic complications constitutes reperfusion injury.  Ischaemia reperfusion 
injury was first described in a canine myocardial model by Cerra et al in 1975 
(Cerra et al. 1975). Specifically, they observed that reperfusion after prolonged 
ischaemic anoxia, produced sub-endocardial haemorrhagic necrosis, the extent of 
which was proportional to the duration of the preceding ischaemic event.  
Further to this, a retrospective review of the mortality from valve replacement 
surgery, deduced that 30% of the deaths were due to post bypass haemorrhagic 
necrosis (Cerra et al. 1975).  May and colleagues (May et al. 1978) first 
described the phenomenon of reperfusion injury in a free flap model, where they 
observed progressive obstruction of peripheral blood-flow in the flaps with 
increasing periods of ischaemia, up to a point where irreversible ischaemia and 
tissue necrosis occurred. 
 
We know that an extended period of ischaemia damages cells, however 
paradoxically; reintroduction of oxygenated blood to ischaemic tissue results in 
further damage and can be lethal.  Piper (Piper et al. 1998) defines reperfusion 
injury as “injury caused by restoration of blood flow after an ischaemic episode 
leading to death of cells that were only reversibly injured during that preceding 
ischaemic episode”.  There has been much debate by investigators in the past 
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regarding the existence of reperfusion injury and the timing of lethal injury to 
cells during an ischaemic insult.  In the past it was believed that all cellular 
injury developed during the ischaemic period whereas we now contend that 
reperfusion extends, and in fact contributes to the majority of tissue injury.  Gute 
et al demonstrated that the characteristic myonecrosis of reperfusion injury will 
not occur in ischaemic skeletal muscle unless exposed to molecular oxygen by 
reperfusion (Gute et al. 1998).  Tissue damage by reperfusion injury arises via a 
complex series of mechanisms.  The earliest moments of I/R injury are 
characterised by a ‘respiratory burst’ with inflammatory cascades and release of 
reactive oxygen species (ROS), followed by mitochondrial dysfunction and 
eventually disruption of the microcirculation (no-reflow phenomenon) (Khalil et 
al. 2006; Gross et al. 2007). 
 
 
1.2.3.1   Generation of Reactive Oxygen Species (ROS) 
 
ROS are highly unstable oxygen molecules with unpaired electrons.  They are 
produced in small quantities by normal cellular metabolism and are tightly 
regulated by ROS scavengers such as glutathione, superoxide dismutase and 
catalase (Granger et al. 1986). During ischaemia reperfusion injury sufficiently 
large quantities of ROS are produced which overwhelm the endogenous 
scavengers and therefore exert their effects on the cell. 
 
Depending on the tissue in question, there are different sources of ROS.  For 
example, following reperfusion injury in the lung the main source of ROS is 
cytochrome P450, whereas xanthine oxidase and NADPH oxidase have been 
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identified as important sources of ROS in skeletal muscle (Khalil et al. 2006; 
Zweier et al. 2006). 
 
Xanthine oxidase (XO) is an enzyme located mainly within endothelial cells, in 
cardiac as well as skeletal muscle (Jarasch et al. 1986).  During early reperfusion 
XO reacts with the anaerobic breakdown products of ATP, hypoxanthine and 
xanthine, to form hydrogen peroxide (Zweier et al. 2006).  The localisation of 
XO to endothelial cells and their early exposure to oxygenated blood suggests 
their susceptibility to ROS-mediated reperfusion injury.  The resultant 
endothelial cell damage may induce inflammatory cell chemotaxis, propagating 
the reperfusion injury. 
 
Nicotinamide adenine dinucleotide phospate (NADPH) oxidase is another 
enzyme bound to phagocytic leucocytes.  Neutrophil accumulation is a 
recognised sequelae of reperfusion injury, and therefore the increase in oxygen 
metabolism associated with the ‘respiratory burst’ results in oxidation of 
cytoplasmic NADPH to NADP+.  This produces highly unstable superoxide 
anion, which will further react with water and chloride ions to produce hydrogen 
peroxide and hypochlorous acid, respectively (Zweier et al. 2006). 
 
During early reperfusion, the increased production of ROS have a direct toxic 
effect on the muscle cell by the process of lipid peroxidation resulting in 
breakdown of the cell membrane’s phospholipid bilayer.  This leads to a loss of 
membrane integrity, disruption of the osmotic gradient, cellular swelling and 
eventual cell death (Park et al. 1999; Zweier et al. 2006). 
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Due to the presence of ROS associated with the ‘respiratory burst’ in early 
reperfusion, several investigators have explored the potential of ROS scavengers 
to reduce reperfusion injury.  There is evidence to show that lipid peroxidation 
can be inhibited by the administration of ROS scavengers, such as Vitamins A/E 
(Bilgin-Karabulut et al. 2001) and prostacyclin (Bozkurt 2002).  However, other 
experiments looking at inhibition of NADPH oxidase (Dodd et al. 2000) and in 
NADPH oxidase-deficient mice (Hoffmeyer et al. 2000), have failed to show 
significant attenuation of reperfusion injury.  
 
Despite xanthine oxidase (XO) being identified as a major pathway for ROS 
generation, the activity of XO is extremely variable, depending on the tissue or 
the species in question. For example, increased levels of the XO have been 
demonstrated in endothelial cells of ischaemic human skeletal muscle by Wilkins 
and colleagues (Wilkins et al. 1993), whereas very minute quantities of XO were 
observed in ischaemic canine skeletal muscle (Lindsay et al. 1990).  This may 
explain the poor results obtained using XO inhibitors to ameliorate the effects of 
reperfusion injury. For example, Allopurinol, a xanthine oxidase inhibitor, failed 
to attenuate the extent of skeletal muscle necrosis in the pig, after 5 hours 
ischaemia and 48 hours reperfusion (Dorion et al. 1993). 
 
It seems that ROS were initially thought to be major effectors of the reperfusion 
injury cascade but the failure to reach a consensus on the effects of ROS 
scavengers, have lead researchers to conclude that ROS are important mediators 
but only a minor contributor to reperfusion injury (Khalil et al. 2006; Zweier et 
al. 2006).  
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1.2.3.2   Mitochondrial Calcium Overload 
 
There is now uniform consensus that calcium (Ca2+) homeostasis is central to the 
development of ischaemia reperfusion injury.  Cytosolic Ca2+ concentration is 
normally regulated by transport into and out of the endoplasmic reticulum or 
sarcoplasmic reticulum (ER/SR). It can also be transported out of cells via 
Na+/Ca2+ exchangers (Berridge et al. 1998). During stress conditions, for 
example during ischaemia, Ca2+ transport can be inhibited or even reversed.  In 
prolonged ischaemia the lack of ATP results in a failure to pump calcium out of 
the cytosol via the Ca2+ pump of the ER/SR, resulting in a relatively higher intra-
cellular Ca2+ concentration.  To compound this the burst of ROS during early 
reperfusion can cause the Na+/Ca2+ exchanger to operate in reverse mode 
resulting in further Ca2+ influx into the cytosol (Ermak et al. 2002).   
 
During ischaemic conditions, Ca2+ influx is essentially limited by intracellular 
acidosis, i.e., anaerobic breakdown of ATP produces an excess of H+, which 
results in a lowering of both the intracellular and extracellular pH.  This ionic 
homeostasis inhibits the cation pumps, namely the Na+/H+ exchanger which in 
turn inhibits the Na+/Ca2+ exchanger, preventing further Ca2+ influx to the 
cytosol.  The resupply of oxygen to the myocyte results in 3 changes within the 
cell: a) resupply of ATP to the cation pumps to initiate recovery of the cation 
balance; b) rapid normalisation of intracellular pH resulting in reactivation of 
Na+/H+ and Na+/Ca2+ exchangers, which will aggravate cytosolic Ca2+ 
accumulation; c) too rapid normalisation of extracellular osmolality resulting in 
hyperosmolar intracellular fluid and cellular swelling.  This is mainly due to the 
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reactivation of the Na+/H+ exchanger and the resultant cytosolic Na+ overload 
(Piper et al. 1998). 
 
It is well recognised that the final event in the reperfusion injury cascade is 
mitochondrial Ca2+ overload resulting in uncoupling of oxidative 
phosphorylation and the inability to synthesise ATP, leading to cell death 
(Ermak et al. 2002).  Ca2+ concentrations in the mitochondria are dependent on 
those in the cytoplasm and therefore, under oxidative stress, mitochondrial Ca2+ 
accumulation can change from a physiological beneficial process to a cell death 
signal.   
 
The inner membrane of the mitochondria is impermeable to almost all 
metabolites and ions under normal physiological conditions.  Under certain 
pathological conditions, such as ischaemia, protein pores are formed within this 
membrane.  They are collectively known as the mitochondrial permeability 
transition pore (mPTP) and play a vital role in both active and programmed cell 
death during reperfusion injury.  mPTP can be induced by ROS or a high 
cytosolic Ca2+ concentration (Gateau-Roesch et al. 2006) and can be closed / 
blocked by acidosis and drugs such as Cyclosporin A (Halestrap et al. 1997).  
This illustrates that mPTP remain closed during ischaemia, but open during 
reperfusion.  If the ischaemia reperfusion insult is severe and the mPTP remain 
open and disrupt the mitochondrial membrane potential.   Mitochondria become 
uncoupled and hydrolyse ATP instead of synthesising it, leading to rapid ATP 
depletion, resulting in a loss of structural integrity and necrosis of the myocyte 
(Halestrap et al. 2000).   
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Programmed cell death or ‘apoptosis’ is also mediated via the mPTP.  As 
apoptosis is an energy-dependent process, this may only occur if mPTP opening 
is less extensive or if they are able to reclose following a period of opening.  
Under stress conditions, the mPTP open to allow equilibration of matrix 
proteins.  The osmotic force of these proteins may result in irrecoverable 
mitochondrial swelling and breach of the outer membrane with efflux of 
cytochrome C and other transcriptional factors that cause apoptotic cell death 
(Halestrap et al. 2000; Gateau-Roesch et al. 2006). 
 
 
1.2.4 Late Ischaemia Reperfusion Injury 
 
A later phase of reperfusion injury is thought to come about by the activation and 
invasion of neutrophils.  The time-period of this response is variable, due to the 
multifactorial nature of the inflammatory response from myocyte necrosis. It is 
no surprise that polymorphonuclear (PMN) leucocytes accumulate gradually 
during prolonged ischaemia, as it is simply an inflammatory response like in any 
other tissue. During reperfusion, there are established interactions between 
neutrophils and vascular endothelium. Vascular endothelial cells provide an 
anchoring site for neutrophils by the increased expression of P / L selectin 
molecules (Lefer et al. 1994). This leads to activation of the inflammatory 
cascade, endothelial cell dysfunction and eventually cell death (Vinten-Johansen 
et al. 2005).  
 
It is well known that granulocytic infiltration, predominantly neutrophilic, is a 
hallmark of myocardial infarction, appearing in the first 24 hours after vessel 
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occlusion (White et al. 1936).  However, it is this intensive neutrophil 
accumulation during reperfusion, which has divided opinion on the role of 
neutrophils in reperfusion injury.  Neutrophils are known to be a rich source of 
several ROS, such as superoxide, hypochlorous acid and lysosomal proteolytic 
enzymes (Baxter 2002). This has propagated the idea that neutrophil 
accumulation during reperfusion accounts for the burst of reactive oxygen 
species (ROS) resulting in early lethal reperfusion injury (Lucchesi et al. 1989; 
Reimer et al. 1989; Gumina et al. 1997).  However, further research has failed to 
corroborate these findings and has not been able to robustly reproduce this 
phenomenon.  As well as this the advent of isolated, buffer-perfused hearts, 
devoid of blood components demonstrates that reperfusion injury can be 
replicated in the absence of PMN (Xu et al. 2000; Vinten-Johansen 2004).   
 
 
1.2.4.1 No reflow phenomenon 
 
The “no reflow” phenomenon was first described by Ames in 1968 (Ames et al. 
1968).  He used this term to describe the total occlusion of ischaemically 
damaged capillary networks in the brain.  The pathology of no reflow was first 
properly investigated by Kloner and colleagues in a canine coronary artery 
occlusion model, reporting that, following prolonged ischaemia, a distinct area 
of perfusion deficit was detected following restoration of coronary blood flow 
(Kloner et al. 1974).  It is preceded by changes in the microcirculation that 
develop progressively during the ischaemic insult.  Specifically, the formation of 
endothelial vesicles, differential endothelial swelling and development of gaps 
between cells, leads to an increase in vascular permeability.  This results in 
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haemoconcentration and rouleau formation of red cells, leading to thrombosis 
(Hammersen et al. 1983).  Neutrophil plugging is apparent in the capillaries of 
these areas of no reflow with some interstitial migration of these cells as well.  
Again, there is controversy as to whether no reflow occurs as a result of muscle 
infarction, or muscle necrosis occurs due to inadequate perfusion as a result of 
no reflow (Blaisdell 2002).  We believe that these microvascular changes are 
occurring in areas of critically / irreversibly ischaemic muscle and are therefore a 
consequence of rather than a cause of this phenomenon. 
 
 
1.2.4.2 Distant site injury 
 
If a sufficiently large volume of muscle is involved in the ischaemic process the 
inflammatory response may become systemic.  For example, in compartment 
syndrome or limb replantation, a large mass of skeletal muscle may be 
reperfused with the “washing out” of muscle breakdown products into the 
bloodstream. 
 
Initially, this leads to a profound metabolic acidosis associated with 
hyperkalaemia, lactate acidosis and a systemic coagulopathy due to disseminated 
intravascular coagulation (DIC) (Walker 1986).   The procoagulant breakdown 
products activate other inflammatory mediators in parallel, such as histamine, 
complement, thromboxane and bradykinin.  These mediators create further 
damage to the vascular endothelium, leading to increased systemic vascular 
permeability (Blaisdell 2002; Khalil et al. 2006).  
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The clinical manifestations of this injury occur in the lung and kidney. 
Myoglobin is a direct renal tubular toxin that is released into the bloodstream 
during reperfusion and, in association with acidosis and oliguria, can ultimately 
lead to renal failure (Walker 1986).  Elsewhere, activated neutrophils sequester 
in the lungs and, with concomitant ROS and cytokine damage, cause non-
cardiogenic pulmonary oedema (Khalil et al. 2006).  These sequelae can be fatal, 
even with modest ischaemia periods and young fit patients (McNeill et al. 1970).  
Blaisdell therefore advocates reperfusion of an ischaemic limb, only if the 
ischaemia time is less than 4-6 hours (Blaisdell 2002). 
 
 
 
1.3  Protection of Skeletal Muscle Against Perioperative Ischaemia 
Reperfusion Injury 
 
Ischaemia reperfusion injury can have devastating effects on different tissues and 
organs in the body, and this pathological process is evident in different medical / 
surgical specialties.  For example, in cardiothoracic surgery, prolonged 
myocardial ischaemia during coronary bypass surgery can result in extended 
sub-endocardial necrosis upon reperfusion.  Also, following lower limb trauma, 
patients that undergo limb revascularisation after prolonged ischaemia can suffer 
systemic dysfunction to distant organs, with reperfusion of a large mass of 
skeletal muscle.  Conventional surgical wisdom is to minimise the ischaemic 
insult to the tissues with early reperfusion, however this is often beyond the 
surgeon’s control.  Several therapeutic strategies have been attempted to reduce 
the local and systemic effects of ischaemia reperfusion, such as limb cooling 
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(Sapega et al. 1988) and intra-arterial flushing (Rosen et al. 1987), producing 
mixed results in animal studies.  Heparin anticoagulation, thrombolysis and 
angioplasty is the modern cornerstone of clinical intervention in the treatment of 
ischaemia reperfusion injury of the myocardium, however, although this restores 
blood flow to the ischaemic tissue to reduce the ultimate infarct size, it does not 
prevent the prior damaging effects of the ischaemic insult.   There has therefore 
been a drive for other intervention strategies to try to prevent the effects of a 
prolonged ischaemic myocardial insult, which has translated to several treatment 
strategies targeting ischaemia reperfusion injury affecting skeletal muscle.  
 
 
 
1.4  Acute Ischaemic Preconditioning 
 
In 1986, a landmark study was published by Charles Murry, describing a 
potential treatment strategy, which he termed ‘ischaemic preconditioning’ (IPC) 
(Murry et al. 1986).  In a canine myocardial model, the heart was exposed to four 
brief 5 min periods of alternating coronary artery occlusion and reperfusion, 
prior to an ischaemic insult of 40 min sustained coronary artery occlusion 
followed by 72 hours reperfusion. This resulted in a 75% reduction in 
myocardial infarct size, compared to ischaemic controls.  The same group went 
on to show that this phenomenon was associated with reduction of myocardial 
energy demand during ischaemia and preservation of ATP (Murry et al. 1990). 
 
The discovery of IPC was a huge breakthrough, as previously there had been no 
effective therapeutic intervention to protect tissue from ischaemia reperfusion 
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injury.  The clinical significance of an intrinsic intervention that produced a 75% 
infarct reduction rate was quickly realised, sparking a surge in research using 
myocardial animal models.  This was a potential therapeutic strategy to reduce 
the extent of reperfusion-induced sub-endocardial necrosis in patients 
undergoing coronary angioplasty.  Crucially, IPC is reliably reproducible and has 
been shown to limit infarct size in every species tested to date, such as in the rat 
(Yellon et al. 1992), rabbit (Liu et al. 1991), dog (Murry et al. 1986) and pig 
(Schott et al. 1990). 
 
Acute IPC, also commonly referred to as ‘classical’ IPC, describes a 
preconditioning stimulus performed immediately before the onset of sustained 
ischaemia.  IPC does not completely abolish infarction; rather, it delays the onset 
of cell death by inducing tolerance to ischaemia reperfusion injury. 
 
The translational capability of the IPC phenomenon was quickly realised and in 
1992, Mounsey introduced IPC as a technique to enhance survival in pedicled or 
free skeletal muscle flaps, often used in plastic and reconstructive surgery 
(Mounsey et al. 1992).  Mounsey and colleagues also described a porcine model, 
using the latissimus dorsi skeletal muscle flap to study the preconditioning effect 
(Mounsey et al. 1992).  The pig is a reliable model to study skeletal muscle IPC 
as its musculoskeletal and vascular anatomy closely resemble that of humans.  In 
our lab, Pang and colleagues (Pang et al. 1995) reported that at least three cycles 
of 10 minutes ischaemia and 10 minutes reperfusion were required for 
preconditioning of both latissimus dorsi (LD) and gracilis muscles against a 4 
hour ischaemic insult followed by 48 hours reperfusion.  They reported a 44% 
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and 62% decrease in the extent of infarction in LD and gracilis flaps, 
respectively. 
 
 
1.4.1 Efficacy 
 
The number of preconditioning cycles as well as the duration, has importance in 
relation to the degree of infarct protection, and using too many cycles has been 
demonstrated to abolish the protective effects of IPC (Iliodromitis et al. 1997).  
There has been much debate about the optimum number of cycles of IPC 
required to exert a protective effect over myocardial / skeletal muscle from 
subsequent ischaemia reperfusion injury.  In the canine myocardial model, Li et 
al (Li et al. 1990) demonstrated that a single cycle of 5 min IPC was as effective 
as six or twelve cycles in reducing the rate of infarction following an ischaemic 
insult of 60 mins.  In the rabbit myocardial model, Downey’s group were able to 
afford protection of myocardium with a single cycle of 5 min ischaemia / 10 min 
reperfusion (Liu et al. 1991; Thornton et al. 1993).  On the other hand, two or 
more cycles of IPC are required to significantly protect porcine myocardium 
(Schott et al. 1990; Miyamae et al. 1993); and five cycles of 5 min ischaemia / 5 
min reperfusion were required to effectively precondition in vivo rat hearts (Piot 
et al. 1997).  When translating this to skeletal muscle preconditioning, Pang 
demonstrated that at least 3 cycles of 10 mins ischaemia / 10 mins reperfusion 
were required to effectively precondition porcine latissimus dorsi skeletal muscle 
flaps (Pang et al. 1995). Therefore, it appears that the threshold for IPC is both 
tissue and species-specific. 
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Investigators were initially looking at the myocardium as a recipient tissue of the 
IPC stimulus, instigated by occlusion and reperfusion of coronary vessels.  
However, in 1993 Przyklenk et al noted that IPC by cycles of occlusion / 
reperfusion of the circumflex artery in the dog, additionally protected the area of 
myocardium perfused by the left anterior descending artery (Przyklenk et al. 
1993).  This was termed ‘intraorgan’ remote IPC and lead to further 
investigation with the discovery of ‘interorgan’ remote IPC.  Specifically, 
occlusion / reperfusion of the mesenteric artery in the rat (Gho et al. 1996) or the 
renal artery in the rabbit (Takaoka et al. 1999), protected the myocardium against 
subsequent ischaemia reperfusion.  This form of IPC once again translated 
between species and was also effective in skeletal muscle, where Addison et al 
demonstrated that 3 cycles of 10 min occlusion / reperfusion of a hind-limb 
using a pneumatic tourniquet, significantly reduced infarct size in porcine LD, 
gracilis and rectus abdominis flaps, subjected to a 4 hr ischaemic insult followed 
by 48 hr reperfusion (Addison et al. 2003). 
 
The common endpoint measured to demonstrate the efficacy of IPC in different 
species and tissues is the percentage of infarcted to viable muscle and then 
comparing this with the time-matched ischaemic control.  In addition to infarct 
reduction, IPC is also associated with preservation of ATP content in myocardial 
(Murry et al. 1990) and skeletal muscle (Pang et al. 1995; Addison et al. 2003); 
as well as a reduction in neutrophil accumulation during reperfusion (Pang et al. 
1997; Addison et al. 2003).  Charles Murry’s original paper reported a 75% 
reduction in the infarct size of preconditioned canine hearts (Murry et al. 1986) 
which is similar to the 78% reduction seen in ischaemic preconditioned porcine 
hearts by Schott (Schott et al. 1990).  These 2 papers were seen as the gold 
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standard for IPC efficacy and other myocardial models have attempted to 
achieve this same degree of infarct reduction.  Unfortunately, when translated to 
skeletal muscle infarct protection we see more modest reductions in infarction 
rate with Pang (Pang et al. 1995) reporting a 44% and 62% reduction in total 
infarct size in LD and gracilis muscles, respectively. 
 
 
1.4.2 Mechanism 
 
Ischaemia reperfusion injury has a multi-factorial pathway and as such, IPC can 
have more than one targeted therapeutic effect.  The general consensus is that 
IPC is due to a signal transduction cascade, involving triggers during the 
preconditioning ischaemia (e.g. Adenosine A1 receptor), a cascade of various 
mediators (e.g. Protein Kinase C) converging on end-effectors (e.g. ATP-
sensitive Potassium channels).   The overall effects are a reduction in the rate of 
ATP depletion in the cell as well as preservation of intracellular pH, resulting in 
stabilisation of mitochondrial membranes (Auchampach et al. 1993).  The 
important triggers, mediators and end effectors are detailed below. 
 
Adenosine receptors are found ubiquitously throughout the body in a variety of 
tissues.  There are four subtypes with types 1 and 2 being found in myocardial 
and skeletal muscle.  Stimulation of the A1 receptor causes a profound reduction 
in heart rate via inhibition of conduction of electrical impulses via the Sino 
Atrial Node (SAN) (Auchampach et al. 1993).  The activated A1 receptors are 
also known to couple to a variety of inhibitory G-proteins (Gi proteins) which 
result in inhibition of ATP conversion to camp, i.e. ATP conservation.  These Gi 
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proteins can also be bound and activated by opioids, noradrenaline and 
bradykinin.  Another Gi protein coupled by A1 receptors causes opening of the 
KATP channels, representing another avenue to conserve ATP. This illustrates that 
multiple receptors work in parallel to trigger preconditioning, which is important 
as pharmacological blockade of one receptor type does not completely block 
IPC-induced protection, but serves to increase the ischaemic threshold required 
to trigger protection (Yellon et al. 2003). 
 
Acute adenosine treatment has been highlighted as a mimicker of IPC by 
initiation of signal transduction involving Protein Kinase C (PKC) and resulting 
in activation / opening of KATP channels. Adenosine is therefore responsible for 
the anti-infarctive effects in several myocardial models, such as the dog 
(Auchampach et al. 1993); rabbit (Liu et al. 1991) and pig (Van Winkle et al. 
1994); but not in the rat heart model (Li et al. 1993).  This triggering mechanism 
is similarly translatable to mammalian skeletal muscle, as Forrest (Forrest et al. 
1997) demonstrated in the porcine LD muscle flap model. 
 
Protein Kinase C (PKC) is one of the most important kinase mediators 
responsible for signal transduction and has been shown to be required for IPC to 
be effective in the rat and rabbit myocardial models (Ytrehus et al. 1994; 
Uchiyama et al. 2003).  Our laboratory investigated PKC involvement in the pig 
skeletal muscle flap model, demonstrating that PKC-inhibitors blocked the 
infarct-protective effects of classical IPC and adenosine-induced IPC (Hopper et 
al. 2000).  Other kinases involved in the signal transduction pathways include 
tyrosine kinase and the mitogen-activated protein kinases (MAPK) (Riksen et al. 
2004). 
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The K+ ion is the major cytosolic and mitochondrial cation, responsible for the 
regulation of energy production and maintenance of cellular Ca2+ homeostasis.  
Mitochondria have K+- impermeable inner membranes and therefore require 
bidirectional K+ cycling via specialised channels. The K+/H+ antiporter is 
responsible for K+ efflux, with K+ entry being regulated by the ATP-sensitive K+ 
channels (KATP channel). These channels were originally described by Noma 
(Noma 1983) in the cardiac sarcolemma of isolated mammalian myocytes and 
were found to be an important regulator of cellular energy metabolism and 
membrane excitability. They have since been described in various other tissues, 
such as pancreatic B cells, vascular smooth muscle, human and animal skeletal 
muscle.   
 
Further to Noma’s description, there are 2 subtypes found in the sarcolemma 
(sKATP) and on the mitochondrial inner membrane (mKATP) (O'Rourke 2004).  
These channels are sensitive to changes in intracellular ATP concentration, i.e., 
the channel is activated (opened) in response to a fall in the intracellular 
concentration of ATP.  Opening of KATP channels in cardiac myocytes during 
ischemia or hypoxia results in a shortening of the cardiac action potential (due in 
part to a prolonged phase 3 repolarisation), a reduction in Ca2+ influx and 
therefore ultimately prevention of cytosolic Ca2+ overload (Noma 1983; Gross 
1995).  These changes during an ischaemic insult result in a slowing of cellular 
ATP catabolism and effectively an increase in myocardial / skeletal ischaemic 
tolerance.   
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The critical role of KATP channel opening in the phenomenon of ischaemic 
preconditioning (IPC) was first demonstrated by Gross and Auchampach in 1992 
in a canine myocardial model.  Specifically, the selective KATP blocker 
Glibenclamide prevented myocardial preconditioning, whether given before or 
after the preconditioning ischaemia (Gross et al. 1992).  This was corroborated 
by Geshi et al (Geshi et al. 1999) and again translated as a critical role in IPC of 
skeletal muscle where an infusion of the KATP channel opener Lemakalim 
mimicked the protective effect of preconditioning in porcine LD skeletal muscle 
flaps subjected to 4 hours ischaemia and 48 hours reperfusion. The 
pharmacological activation of KATP channels was also associated with 
preservation of mitochondrial ATP content and reduction in neutrophilic 
myeloperoxidase (MPO) activity (Pang et al. 1997).  Further to this Moses et al 
demonstrated the central role that the mitochondrial KATP (mKATP) channel 
subtype has in both the trigger and mediator mechanisms of hind-limb remote 
IPC of skeletal muscle in the pig model (Moses et al. 2005). 
 
Although sarcolemmal KATP channels are not specifically involved in the trigger 
and mediator mechanisms of acute or remote IPC, they have been shown to act 
as a trigger for delayed / late phase IPC in rat myocardium (Patel et al. 2005) and 
porcine skeletal muscle (Moses et al. 2005).  They will be discussed in more 
detail in the chapter on late phase IPC. 
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Figure 1.2.  The mechanism of acute / classical ischaemic preconditioning 
(IPC).  During the IPC stimulus, several triggers are released (adenosine, 
bradykinin, opioids, noradrenaline).  They activate a complex signaling cascade 
of protein kinases (PI3-kinase, protein kinase c, tyrosine kinases, mitogen-
activated-protein kinases (MAPKs)).  This signaling cascade activates 
mitochondrial KATP channels, which in turn inhibit opening of the mitochondrial 
permeability transition pore (mPTP).  Reproduced from Riksen et al (Riksen et 
al. 2004).  
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1.5  Late Ischaemic Preconditioning 
 
Acute or “classical” IPC describes an immediate adaptation of the cardiac / 
skeletal myocyte to sub-lethal ischaemic stresses.  The acute IPC response 
develops immediately, however, wanes after 2-3 hours.  It was therefore thought 
to be a transient phenomenon until in 1993 when Kuzuya and colleagues noted a 
similar reduction in infarction rate when the sustained ischaemic insult was 
induced 24 hours after the IPC stimulus (Kuzuya et al. 1993).  They termed this 
“delayed” or “late phase” IPC, referring to a second window of preconditioning 
appearing 12-24 hours after the original IPC stimulus.  Further to this, Baxter et 
al discovered that this late phase of protection lasted up to 72 hours, although the 
degree of infarct protection was not quite as robust as classical IPC, with infarct 
size reduction of 50% (Baxter et al. 1997). 
  
Since Kuzuya’s discovery, researchers have found that this biphasic pattern of 
IPC occurs in the myocardium of different species, such as the rabbit (Baxter et 
al. 1997); dog (Kuzuya et al. 1993) and pig (Tang et al. 1996).  Following this, 
Moses et al then demonstrated late phase IPC in the porcine LD skeletal muscle 
flap model (Moses et al. 2005).  
 
 
1.5.1 Efficacy 
 
The therapeutic potentials of late IPC have been highlighted due to its prolonged 
window of preconditioning as well as its protective effects on muscle infarction 
and contractility.  It has been noted by Roberto Bolli’s group in the porcine 
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myocardial model (Tang et al. 1996) that late IPC protects against “myocardial 
stunning” (hypocontractility) as well as myocardial infarction. Further to this, 
Harralson et al (Harralson et al. 2005) found that late IPC protected rat LD 
muscle contractile function as well as infarct rate.  Specifically, Harralson found 
that LD flaps were protected from infarction for a period of 72 hours, however 
the protection of contractile function lasted only 48 hours.  Baxter and 
colleagues characterised the time course of late IPC in the myocardial rabbit 
model (Baxter et al. 1997).  They noted a prolonged “second window” of infarct 
protection 24 – 72 hours following the IPC stimulus.  This protective effect was 
then lost at 96 hours.  Moses et al (Moses et al. 2005) confirmed this time-course 
in the porcine LD muscle flap model and noted that the degree of late-phase 
infarct reduction of 40-47% was similar to the 52% infarct reduction seen with 
acute IPC.  
 
A further therapeutic potential that can be exploited with late-phase IPC, is the 
ability to repetitively precondition cardiac or skeletal muscle to convey a 
continuous period of infarct protection.  This was illustrated by Derek Yellon’s 
team in London, where they showed that intermittent pharmacological IPC, by 
activation of adenosine A1 receptors, over a 10-day period maintained rabbit 
myocardium in a preconditioned state against ischaemia reperfusion injury 
(Dana et al. 1998).  This could make late-phase IPC a powerful clinical tool in 
the realm of cardioprotection as well as augmentation of free flap ischaemic 
tolerance (Figure 1.3). 
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Figure 1.3.  The ischaemic preconditioning (IPC) stimulus can be repeated to 
potentially prolong the “preconditioned” state as well as providing a more 
robust protection of skeletal muscle from ischaemia reperfusion, during the 
second window of protection.  
 
 
1.5.2 Mechanism 
 
Investigators have shown that classical and late-phase IPC mostly share the same 
signal transduction cascade involving various kinases, however the triggering 
stimuli and end effectors differ.  The most striking difference between classical 
and delayed IPC is the activation of important transcriptional regulators, such as 
nuclear factor-kB (Riksen et al. 2004), in the cell nucleus resulting in increased 
transcription of protective proteins and genetic modification of the myocyte to a 
more ‘defensive’ ischaemically tolerant phenotype.  Several studies have looked 
at the triggering mechanism of this complex cascade.  Baxter was the first to 
report that Adenosine, as well as in acute IPC, initiates late IPC (Baxter et al. 
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1994).  The same group went on to classify the A1 subtype responsible for 
triggering the delayed protection (Baxter et al. 1997).  Bolli’s group identified 
another important trigger, Nitric Oxide (NO) (Qiu et al. 1997).  NO is an organic 
nitrovasodilator that can be formed endogenously by Nitric Oxide Synthase 
(NOS).  There are three isoforms of this enzyme: neuronal (nNOS), endothelial 
(eNOS) and inducible (iNOS).  NO is a cell-signaling molecule that can be best 
described as an endogenous modulator of vascular tone. Bolli has shown that 
myocardial adaptation to an ischaemic stress is due to an upregulation of eNOS, 
generating NO, which in turn triggers the kinase cascade leading to protein 
synthesis (Bolli et al. 1997).  The involvement of NO as a trigger is further 
illustrated by the use of exogenous NO donors to mimic late IPC (Wang et al. 
2000; Xuan et al. 2007). 
 
The mediators of late IPC are described as the upregulated proteins that will 
enhance the tolerance of the cell to subsequent ischaemia.  How they provide 
protection is still not fully understood.  Interestingly NO has been identified as a 
mediator as well as trigger in the late IPC cascade.  Takano et al (Takano et al. 
1998) reported that iNOS was involved in the mediator mechanism of late IPC in 
the rabbit myocardial model.  Other downstream mediators have been 
highlighted and are noted to be upregulated in preconditioned animals, such as 
Cyclooxygenase-2, superoxide dismutase and Aldose Reductase.  There is a 
diversity of IPC initiators and mediators that converge on a common end-
effector pathway resulting in KATP channel activation. 
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Figure 1.4.  The mechanism of delayed / late-phase ischaemic preconditioning 
(IPC).  Nitric Oxide (NO) is an important additional trigger in delayed IPC.  The 
kinase signal transduction cascade leads to activation of transcriptional 
regulator nuclear factors, which cause increased synthesis of protective 
proteins.  Several mediators converge on a final common end-effector pathway 
resulting in mitochondrial KATP channel (mKATP) activation. Reproduced from 
Riksen et al (Riksen et al. 2004).  
 
 
It has been universally agreed that KATP channel opening is the final common 
pathway on which the signaling cascades converge, however, it remains to be 
determined whether its contribution is similar to that in acute IPC, where it has 
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been reported to inhibit ROS-induced mPTP opening during early reperfusion 
(Hausenloy et al. 2003). 
 
Mei et al (Mei et al. 1996) were the first group to demonstrate that KATP channel 
activation was involved in the mediator pathway of late IPC. However, it was 
not until the more recently that mitochondrial KATP channels (mKATP) were 
highlighted as the likely mediator / end-effectors of late IPC (Bernardo et al. 
1999; Takashi et al. 1999).  This was facilitated by the development of highly 
selective pharmacological openers and inhibitors of mKATP channels, namely 
Diazoxide (Takashi et al. 1999) and 5-hydroxydecanoate (Takano et al. 2000). 
These mKATP channels, found on the inner membrane of the mitochondria, are 
postulated to act as a mechanism for osmotic regulation of mitochondrial volume 
and ultimately for mitochondrial Ca2+ homeostasis.  Activation of these channels 
in mitochondria isolated from cardiac muscle, report membrane depolarisation 
produced by the K+ entry, leading to reduced mitochondrial Ca2+ entry through 
the Ca2+ uniporter and further release of accumulated mitochondrial Ca2+ stores 
(Holmuhamedov et al. 1998; Holmuhamedov et al. 1999).  
 
The translational skeletal muscle studies were carried out by Moses et al where 
they demonstrated, using the same pharmacological probes, that mitochondrial 
KATP channels play a central role in the mediator mechanism of late phase IPC in 
the protection of porcine skeletal muscle from infarction.  Pharmacological 
activation of these channels was associated with muscle ATP preservation during 
sustained ischaemia and reperfusion, as well as a reduction in neutrophil 
accumulation during reperfusion (Moses et al. 2005). 
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The role of KATP channels in the triggering mechanism of delayed IPC was first 
examined by Garrett Gross’ group in 2004.  Specifically, they showed that 
administration of the selective sarcolemmal KATP (sKATP) channel blocker HMR-
1098, but not 5-HD (mKATP blocker), abolished the IPC-induced infarct 
reduction 24 hours after the IPC stimulus (Patel et al. 2005).  Using these same 
pharmacological probes, Moses et al further qualified the role of sKATP in the 
trigger mechanism of late phase IPC in the porcine LD skeletal muscle model 
(Moses et al. 2005).  
 
 
 
1.6 Pharmacological Conditioning Against Perioperative Ischaemia 
Reperfusion Injury 
 
Since the discovery of acute and late-phase IPC, researchers have elucidated a 
complex multi-factorial molecular mechanism associated with this phenomenon.  
These findings have provided us with several targets for pharmacological 
intervention and a huge clinical potential in the treatment of myocardial disease 
as well as the prevention of reperfusion-induced necrosis in musculoskeletal 
reconstructive surgery.   
 
Acute IPC increases the ischaemic tolerance of a myocyte by subjecting it to 
sub-lethal periods of ischaemia prior to a sustained ischaemic insult.  This is 
performed by invasively occluding and reperfusing the coronary vessels in a 
myocardial model, or the vascular pedicle in a skeletal muscle flap model.  
Performing this in a clinical human setting would be extremely invasive and 
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risks intimal damage to delicate vascular pedicles.  Therefore the roles of various 
pharmacomimetics have been investigated in their capacity to pharmacologically 
precondition myocardial / skeletal muscle against I/R injury. 
 
 
1.6.1 History 
 
Despite the early interest in the role of oxygen-derived free radicals (now 
collectively known as “reactive oxygen species”), there has been little advance in 
pharmacological therapy to combat ROS-mediated I/R injury. For example, the 
roles of xanthine oxidase and NADPH oxidase are known as important sources 
of ROS, however, inhibition of these enzymes has failed to attenuate ischaemia 
reperfusion in different species (Dorion et al. 1993; Dodd et al. 2000; Hoffmeyer 
et al. 2000). 
 
The first major advance was the discovery of the Adenosine A1 receptor 
involvement in the trigger mechanism.  Researchers were then able to mimic the 
IPC response by using both exogenous Adenosine (Forrest et al. 1997) and a 
specific Adenosine A1 agonist (Auchampach et al. 1993; Tsuchida et al. 1993).  
However, due to the short elimination time of Adenosine, it is not really suitable 
for administration to elicit pharmacological IPC.  Instead, the extracellular 
concentration of endogenous Adenosine can be pharmacologically raised by the 
nucleoside transport inhibitor Dipyridamole, which has shown promising results 
in a rabbit myocardial I/R model (Miura et al. 1992).  Other IPC triggers prone 
to pharmacologically activation are:  Bradykinin (elevated by the inhibited 
breakdown by ACE inhibitors (Jaberansari et al. 2001)); Morphine, as an opioid 
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agonist (Schultz et al. 1996); and Nitroglycerin as a NO donor (Leesar et al. 
2001).   
 
Downstream in the signal transduction pathway is the stimulation of Protein 
Kinase C (PKC), a series of iso-enzymes that play an important role as 
secondary messengers in the signal transduction cascade of IPC.  Downey’s 
group demonstrated that pharmacological activation of PKC mimicked IPC in 
rabbit myocardium (Ytrehus et al. 1994).  Further to this, our lab demonstrated 
that pharmacological activation of PKC resulted in infarct protection of porcine 
LD muscle via a KATP channel-opening mechanism (Hopper et al. 2000).  
Despite the range of pharmacological ‘triggers’ of IPC that have been 
investigated, more recently the focus has been on studying pharmacological 
activation of the end-effectors of classical and delayed IPC. 
 
One of the final events in the pathogenesis of I/R injury is mitochondrial Ca2+ 
overload, preceded by cytosolic Ca2+ overload (Ermak et al. 2002).  The Na+/H+ 
ion exchange protein (NHE) plays a central role, along with the Na+/Ca2+ 
exchanger, in the maintenance of intracellular pH, Na+ and Ca2+ content.  
Pharmacological inhibition of the NHE before ischaemia results in protection of 
the myocardium from I/R injury in the pig model (Rohmann et al. 1995).  
Further to this, in our lab we demonstrated in our porcine skeletal muscle model, 
that the selective NHE inhibitor Cariporide protected LD muscle flaps from I/R 
injury when administered before ischaemia or reperfusion (McAllister et al. 
2008). 
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As described earlier, the opening of mitochondrial KATP channels (mKATP) is 
essential for both acute and late-phase IPC to occur.  Therefore recent effort has 
gone into the exploration of various pharmacological mKATP openers as well as 
inhibitors, which can arrogate or abolish the preconditioning stimulus.  For 
example Glibenclamide, one of the sulphonyl ureas used in the treatment of 
Type 2 diabetes, is a potent non-selective KATP channel inhibitor and abolishes 
IPC in both myocardial (Gross et al. 1992; Schultz et al. 1996) and skeletal 
muscle (Pang et al. 1997; Moses et al. 2005; Moses et al. 2005) of numerous 
species.  Diazoxide is a clinically licensed vasodilator has been shown to 
selectively activate mKATP channels (Liu et al. 1998).  There is extensive 
research demonstrating pharmacological preconditioning by Diazoxide in 
myocardial animal models (Takashi et al. 1999; Takano et al. 2000; Rousou et al. 
2004; Tsukamoto et al. 2005).  The other clinically available KATP channel 
activator, which has had more recent clinical focus is Nicorandil and it will be 
discussed in more detail below. 
 
 
1.6.2 Properties 
 
The properties required for a clinically relevant pharmacomimetic are that the 
drug is preferably used in clinical practice already, has a relatively low side-
effect profile and will be able to induce late IPC to augment the ischaemic 
tolerance of the myocardial / skeletal muscle tissue throughout a perioperative 
period, whether this be coronary angioplasty, heart transplantation, or free 
muscle transfer for reconstructive surgery. 
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Specific mKATP openers such as BMS-191095 (Moses et al. 2005) or the sKATP 
channel opener P-1075 (Moses et al. 2005) have shown favourable responses in 
producing infarct reduction comparable to invasive IPC, however, these are non-
licensed drugs that have extensive side-effect profiles.  Diazoxide has shown 
great promise as a pharmacological preconditioning agent for the myocardium 
(Takashi et al. 1999; Takano et al. 2000; Rousou et al. 2004; Tsukamoto et al. 
2005), however, the drug can cause systemic hypotension and also has the 
significant side-effect of inhibiting insulin release from the pancreas, thereby 
raising blood glucose.  Researchers therefore turned to other licensed clinical 
drugs to test in myocardial animal models, such as Nicorandil. 
 
Nicorandil is a nicotinamide nitrate and is a clinically licensed drug used in the 
treatment of angina pectoris.  Nicorandil was initially discovered by Japanese 
investigators and first reported internationally in 1979 as an experimental drug 
SG-75 with the potential as an anti-anginal medication due to its vasodilatory 
properties without calcium antagonism (Yanagisawa et al. 1979).  Initially 
Nicorandil (SG-75) was seen as a new therapy in ischaemic heart disease.  
However, over time the cardioprotective potential has received much more 
attention and is now the main focus for investigators. 
 
Nicorandil is a hybrid drug with both nitrate vasodilator and potassium-channel 
activating properties.  The nitro-vasodilator effects of are thought to act by 
releasing nitric oxide, which in turn up-regulates intracellular cyclic guanine 
monophosphate (cGMP) levels and causes smooth muscle relaxation (Kukovetz 
et al. 1992).  Nicorandil is also a potent ATP-sensitive potassium (KATP) channel 
opener, whose effect results in a shortening of the myocyte action potential 
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duration.  This inhibits calcium influx, causing a reduction in intracellular 
calcium, leading to relaxation of vascular smooth muscle (Kukovetz et al. 1992).  
Clinically the nitrate properties dilate venous capacitance vessels, whereas the 
KATP channel activation leads to dilation of arterial resistance vessels.  Nicorandil 
therefore acts as a balanced coronary artery and peripheral vasodilator, which 
reduces both preload and afterload, ultimately having a reductive effect on mean 
arterial pressure.    
 
Nicorandil has a rapid rate of absorption; the therapeutic dosage range of 5 to 40 
mg reaches a maximal plasma concentration after approximately 30 minutes, and 
this plasma concentration has a linear dose relationship (Frydman 1992).  The 
absolute bioavailability of Nicorandil after both oral and intravenous 
administration in healthy human volunteers is in the region of 75-80%, implying 
there is no significant liver first-pass effect.  Metabolism is by denitration to 
nicotinamide metabolites, which are mainly renally excreted (Frydman 1992).  A 
single dose of the drug is eliminated from plasma within 8 hours, with an 
elimination half-life of 45 minutes after oral or intravenous administration 
(Markham et al. 2000).  Verdouw et al studied the regional and systemic 
haemodynamics of Nicorandil in the anaesthetised and conscious pig.  They 
reported an increase in cardiac output associated with a dose-dependent 
reduction of systemic vascular resistance and mean arterial pressure.  Their 
investigation of the regional haemodynamics found that at the highest doses of 
Nicorandil, there were increases in blood flow to vital organs; however, blood 
flow to skeletal muscle was minimally affected (Verdouw et al. 1987). 
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The current dosage recommendations for human patients with stable angina 
pectoris are 10-30mg twice daily.  The most commonly reported adverse effect is 
headache and dizziness, although there have been reports of patients developing 
aphthous or severe mouth ulceration (Markham et al. 2000).  Another rare but 
well-reported complication of chronic Nicorandil treatment is idiopathic perianal 
ulceration (Katory et al. 2005). 
 
The beneficial effects of Nicorandil in myocardial infarct protection were 
actually reported before the phenomenon of IPC was discovered by Charles 
Murry (Murry et al. 1986).  Lamping et al studied the effects of Nicorandil on 
ischaemia reperfusion-induced myocardial infarct size in a canine model.  They 
commented that animals infused with Nicorandil during the ischaemia and 
reperfusion period, had significantly lower infarct size compared to ischaemic 
controls.  They also revealed that this beneficial effect was not related to any 
improvement in myocardial bloodflow (Lamping et al. 1984). 
 
Following the discovery of IPC and the early success of pharmacomimetic 
triggers of IPC, Nicorandil has now emerged as an important new 
pharmacological preconditioning agent.  It has been shown to have a 
cardioprotective effect in several species, such as dog (Mizumura et al. 1995; 
Geshi et al. 1999), rabbit (Ohno et al. 1997; Imagawa et al. 1998) and pig (Galie 
et al. 1995).  In later experiments several of these investigators subsequently 
reported the involvement of KATP channels in the mediator mechanism of 
Nicorandil-induced IPC (Mizumura et al. 1996; Ohno et al. 1997; Imagawa et al. 
1998).  In in-vitro studies using isolated ventricular myocytes, Sato et al have in 
fact reported mKATP channel opening as the likely mediator of Nicorandil-
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induced cardioprotection (Sato et al. 2000; Ishida et al. 2004).  In a similar in-
vitro model, Ishida et al (Ishida et al. 2004) demonstrated that Nicorandil 
attenuates mitochondrial Ca2+ overload via mKATP channel opening, which as we 
know, is a final event in ischaemia reperfusion-induced myocyte necrosis.  
Further therapeutic potential of Nicorandil was realised when Bolli’s group 
demonstrated that Nicorandil could induce the second window of 
preconditioning against myocardial infarction when given 24 hours before the 
onset of sustained ischaemia (Tang et al. 2004).  
 
 
1.7  Rationale 
 
Elective autogenous muscle transfer is employed frequently in plastic and 
reconstructive surgery to reconstruct form and/or function.  Since the 1970s, free 
tissue transfer has evolved and become one of the modern cornerstones of 
reconstructive surgery.  Skeletal muscle flaps are useful as their bulk lends itself 
to reconstruction of large defects, as well as neurotisation of flaps to provide 
functional muscle reconstruction in cases such as facial palsy and Volkmann’s 
contracture.  With meticulous planning and technique, the obligatory ischaemic 
interval in free tissue transfer can be kept to a minimum and the overall failure 
rate has now improved in recent years to around 5% (Khouri et al. 1998).  
However, unforeseen complications can occur to prolong this ischaemic interval, 
such as vascular thrombosis.  This is a more common complication of free tissue 
transfer with thrombosis rates of 8-10%, necessitating salvage surgery (Khouri et 
al. 1998; Selber et al. 2012).  The vast majority of these complications occur in 
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the first 48 hours post operatively and this has been suggested as the ‘golden 
period’ for salvage of a free flap compromised by pedicle thrombosis. 
 
In vascular, orthopaedic and plastic surgery, the use of pneumatic tourniquets is 
commonplace to provide a bloodless field during an operation.  These 
tourniquets often remain inflated for a duration of 2-3 hours, seen as the 
acceptable upper limit of tourniquet time (Klenerman 1980), but resulting in 
prolonged warm ischaemia with accompanied metabolic changes in 
compartments of muscles in the lower / upper limb (Ostman et al. 2004). These 
changes occur due to the high metabolic demands of skeletal muscle, which is 
known to have a relatively short critical ischaemic period of 2.5 hours, compared 
to other tissues (Sjostrom et al. 1982). 
 
Since the advent of free tissue transfer, plastic surgeons have been looking for 
ways to protect skeletal muscle and composite tissue flaps from ischaemia 
reperfusion injury.  Except for the early restoration of blood-flow to the flap / 
muscle there has been little else available to be used as a direct therapeutic 
intervention.  The significant breakthrough was the discovery of ischaemic 
preconditioning by Murry et al in 1986, whereby subjecting a tissue to brief sub-
lethal cycles of ischaemia, results in robust infarct protection against a 
subsequent ischaemic insult (Murry et al. 1986).  Following this discovery of an 
immediate adaptation in a tissue’s ischaemic tolerance, Kuzuya (Kuzuya et al. 
1993) revealed that the IPC phenomenon was biphasic, with an initial ‘acute’ 
preconditioning effect, waning after 4-6 hours, and returning at 12 – 24 hours 
following the preconditioning stimulus/treatment. The further discovery that this 
second window of protection lasts for up to 72 hours (Baxter et al. 1997; Moses 
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et al. 2005) makes late phase IPC more applicable for clinical practice, 
maintaining a continuous level of ischaemic tolerance within the tissue for at 
least 48 hours. 
 
Acute / classical IPC, as described by Murry, requires a fairly invasive procedure 
to instigate the protection, involving repetitive clamping of coronary vessels or 
vascular pedicles.  It would be difficult to convince a microsurgeon to perform 
repetitive clamping on the delicate vascular pedicles of free flaps!  It was not 
until Przyklenk et al (Przyklenk et al. 1993) coined the term ‘remote IPC’, where 
a distant site to the preconditioned area is also protected, did a potential for 
practical clinical use become more accepted.  This new finding was adapted by 
Addison et al (Addison et al. 2003), when remote IPC was induced using a hind-
limb tourniquet in the porcine skeletal muscle flap model.  Further to this, Moses 
et al combined these 2 evolutions in IPC, employing the hind-limb tourniquet 
technique to instigate late-phase infarct protection by remote IPC (Moses et al. 
2005).  This resulted in a robust form of infarct protection over a period of 48 
hours, however, required preliminary animal anaesthesia to perform repetitive 
tourniquet inflations 24 hours before the flap surgery and subsequent ischaemic 
insult (Moses et al. 2005). 
 
With the discovery of pharmacomimetic drugs such as Adenosine (Forrest et al. 
1997) and Diazoxide (Takashi et al. 1999), the next logical step was to simulate 
the preconditioning effect without the need for invasive procedures such as 
vessel clamping or painful prolonged limb tourniquet inflation.  Scientists have 
strived to find a suitable pharmacomimetic drug that will simulate the 
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preconditioning effect and provide a robust form of infarct protection over a 
prolonged period of time. 
 
Nicorandil, a currently licensed anti-anginal medication, has been extensively 
studied in myocardial preconditioning models (Galie et al. 1995; Mizumura et al. 
1996; Ohno et al. 1997; Imagawa et al. 1998; Geshi et al. 1999). The mechanism 
responsible for this pharmacological effect is via activation of ATP sensitive K+ 
channels and Nicorandil has additionally been shown to produce a robust second 
window of infarct protection in a rabbit myocardial model (Tang et al. 2004).  
Incidentally, Moses et al demonstrated the central role of ATP sensitive K+ 
channels in the mechanism of late-phase IPC of porcine skeletal muscle (Moses 
et al. 2005). As the efficacy and mechanism of acute and late-phase IPC 
translates from myocardial to skeletal muscle, it is feasible that Nicorandil would 
be able to induce a robust period of infarct protection in a skeletal muscle flap 
model.  However, to date no studies have looked at Nicorandil-induced late 
phase preconditioning beyond 24 hours in cardiac or skeletal muscle. 
 
 
1.8  Hypothesis 
 
The well validated porcine latissimus dorsi skeletal muscle flap model will be 
used in order to examine the hypothesis that a single intravenous injection of 
Nicorandil will induce biphasic ischaemic preconditioning, with a second (late) 
phase that is robust enough to provide at least 48 hours continuous infarct 
protection of skeletal muscle from an ischaemic insult of 4 hours, followed by 48 
hours of reperfusion. 
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It is believed that the mechanism of Nicorandil-induced preconditioning is 
triggered by sarcolemmal ATP-sensitive K+ channels and the end-effector 
mechanism involves opening of mitochondrial ATP-sensitive K+ channels.  It is 
hypothesised that this infarct protection is associated with a reduction in 
mitochondrial calcium overload, a reduction in neutrophil accumulation and 
ultimately preservation of muscle ATP content during early reperfusion. 
 
 
 
1.9 Specific Aims 
 
1. To test the above hypotheses it is intended to use our lab’s well-validated 
porcine LD muscle flap model.  It is planned to validate the consistency 
of this model and to achieve a consistent reliable ischaemic control 
infarction rate with an ischaemic insult of 4 hours followed by 48 hours 
of reperfusion. 
 
2. To test the hypothesis that a single i.v. dose of Nicorandil elicits late-
phase IPC when administered 24 hours before the ischaemic insult.  It is 
intended to demonstrate a linear dose-response relationship of Nicorandil 
with the % reduction in muscle infarction rate, compared to an ischaemic 
control. 
 
3. To test the physiological response of the pig to an intravenous bolus 
injection of Nicorandil, with measurement of the mean arterial pressure. 
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4. To test the hypothesis that a single i.v. dose of Nicorandil elicits a 
biphasic IPC response, with an acute IPC phase and a late / delayed 
phase, which maintains infarct protection for a period of at least 48 hours 
in the porcine model. 
 
5. To test the hypothesis that pharmacological preconditioning with 
Nicorandil involves prevention of mitochondrial free calcium (m[Ca2+]) 
overload, attenuation of neutrophil accumulation and preservation of 
muscle ATP content. 
 
6. To test the hypothesis that sarcolemmal ATP-sensitive K+ channels 
(sKATP) have a role in the triggering mechanism, and mitochondrial ATP-
sensitive K+ channels (mKATP) have a role in the effector mechanism of 
Nicorandil-induced pharmacological preconditioning. 
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2.0 METHODS 
 
2.1 Animal Model 
 
2.1.1 Choice of Porcine Model 
 
The pig as an animal model for muscle flap surgery is extremely useful as there 
is a close correlation between the musculoskeletal anatomy, origin/insertion, 
vascular territories and blood/nerve supply of porcine and human skeletal 
muscles (Patterson et al. 1967; Milton 1972; Meyer et al. 1978; Prather et al. 
1979; Millican et al. 1985). Pigs have almost identical macroscopic tissue 
qualities of the skin, fascia and muscle, with the exception of the panniculus 
carnosus: a thin muscular layer adherent to the dermis along the flanks and neck 
of the animal that is useful for shivering and temperature control.  Further 
justification of the porcine latissimus dorsi muscle flap model is discussed later 
in Chapter 4. 
 
We used Yorkshire pigs for our experiments, as they were readily obtainable 
from a local farm in Ontario.  Yorkshire piglets are born in litter sizes of 10-15 at 
around 1.5kg in weight and are weaned at around 35 days of age.  We aimed to 
perform our muscle flap surgery on 18 – 20kg pigs, therefore giving an age 
range of 8 – 10 weeks, using standard growth rate charts (Bell 1964).  The 
Yorkshire breed do not reach sexual maturity until 5 – 6 months of age and 
therefore the animals used in this experiment would be classed as juvenile / 
adolescent (Reiland 1978). 
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All animals were male and castrated to reduce animal aggression and hormonal 
influences, which may have interfered with results.  All the animal surgical 
procedures were performed at the Research Institute of the Hospital for Sick 
Children in Toronto.  The animal lab and staff have extensive training in dealing 
with pigs and have trusted animal suppliers providing healthy vaccinated 
animals.  The facilities enabled initial apprentice-style training in the surgical 
and anaesthetic techniques required for our surgical protocol.  An animal-
handling course was also undertaken with the Research Institute prior to any 
surgical training.  This enabled confident handling, without causing any undue 
stress to the animals. 
 
 
2.1.2 Latissimus Dorsi (LD) Muscle Flap Model 
 
The Latissimus Dorsi (LD) muscle flap model was chosen for this research 
project primarily due to its extensive validation from previous studies performed 
in our lab with the pig model (Mounsey et al. 1992; Pang et al. 1995; Hopper et 
al. 2000; Addison et al. 2003; Moses et al. 2005; McAllister et al. 2008).  Other 
investigators have also reported the use of LD muscle / myocutaneous flaps to 
study critical ischaemia times in porcine skeletal muscle (Zelt et al. 1986; 
Picard-Ami et al. 1990; Thomson et al. 1991).  The LD is a superficial muscle, 
lying just deep to the pannniculus carnosus with borders that are easily palpable 
(Figure 2.1).  The muscle can be easily raised and isolated on its principle 
thoracodorsal pedicle, which also lies superficial to the deep fascia (Getty 1975).  
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Using 18kg animals, one can harvest a reasonable size and thickness of muscle 
flap (13 x 8 cm) for simulating ischaemia/reperfusion injury as well as for 
multiple muscle biopsies.  The muscles are readily accessible through bilateral 
flank incisions and, like human LD muscle, are not vital to general mobility and 
locomotion.  The skin incisions are in such an area that they heal well without 
any undue tension or risk of infection.  
 
 
 
 
Figure 2.1.  The musculoskeletal anatomy of the pig is remarkably similar to 
that of the human.  The Latissimus Dorsi (LD) muscle originates from the lower 
4 ribs, inserting into the humerus.  The principle vascular pedicle is the 
thoracodorsal vessels with secondary intercostal perforator supply.  The muscle 
lies superficially on the flank deep to the pannniculus carnosus and is easy to 
palpate behind the forelimb shoulder (Getty 1975). 
 
 
 
 65 
2.2 Animal Management and Care 
 
Pigs were ordered from a local supplier (M. Allin Farm) and were delivered to 
the animal care facility once per week.  On arrival, the pigs were examined by 
the resident vetinarian and passed fit.  Animals were housed in temperature-
controlled (220C) and light-controlled (07:00 – 19:00) rooms with individual 
pens, for a period of at least 3 days prior to surgery to allow for acclimatisation 
and to alleviate stress from transportation.  All pigs were offered the same 
commercial diet and tap water ad libitum; animals were fasted the night before 
surgery, but water was continued freely until the time of surgery.  Animals were 
transported from their pens to the anaesthetic room in large mobile cages 
 
The experimental surgery and animal management described in the following 
studies was approved by the Animal Care and User Committee of the Research 
Institute, The Hospital for Sick Children, Toronto, Ontario, Canada, and was in 
compliance with the guidelines of the Canadian Council of Animal Care (1980). 
Sacrificed animals were incinerated according to a protocol approved by the 
Animal Care and User Committee.  The animal management and animal surgical 
procedures have been previously reported. 
 
 
2.3 Animal Anaesthesia 
 
2.3.1 Induction 
On the day of surgery fasted animals were brought up to the induction room at 
6:30 – 7:00 am.  An intramuscular “premed” injection was given of Akmezine (1 
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ml contains: Ketamine Hydrochloride 58.82 mg, Acepromazine 1.18 mg, 
Atropine 0.09 mg; dose 1 ml/6 kg body weight) for animal sedation.  The pig 
was then pre-oxygenated with O2 and N20 (1:1 volume).  The posterior auricular 
surface was shaved and intravenous access was gained with a 20/22-gauge 
cannula. General anaesthesia was induced with intravenous pentobarbitone 
sodium (12-15 mg/kg; Ceva Sante Animal, Québec, Canada).  After 
endotracheal intubation (6.0/6.5 Fr orotracheal tube) the pig was ventilated to a 
tidal volume of 15 ml/kg (Airshields ‘Ventimeter’ Ventilator, Pennsylvania, 
USA).   
A preoperative dose of antibiotic prophylaxis was provided at this time with an 
intramuscular injection of 1ml Penicillin G (50,000 units/kg; Véloquinol, 
Lavaltrie, Quebec, Canada).  The flanks were shaved and the animal washed 
with warm water and chlorhexidine soap before being transferred to the 
operating room.  
  
2.3.2 Maintenance 
 
Following arrival in the operating room, the animal was reconnected to the 
ventilator and ventilation pressure set to a 25cm water pressure (tidal volume of 
15ml/kg).  Ventilation rate was set to 14 breaths/min; however, rate was adjusted 
depending on the end-tidal CO2 measurement. Fluid balance and anaesthesia was 
maintained by an intravenous infusion (Harvard Syringe Infusion Pump, Model 
2720, Bard Medical System Division, Massachusetts, USA) of normal saline 
containing pentobarbitone sodium (0.5 – 1.0 mg/kg/hr).  
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Pentobarbitone sodium was selected for maintenance anaesthesia due to its 
common use in large animal surgery as well as our laboratory’s extensive 
experience using the drug.  Pentobarbitone is a short-acting barbiturate that 
produces steady-state anaesthesia, with minimal haemodynamic fluctuation.  
Traditional volatile anaesthesia was not used due to several reports that volatile 
anaesthetic agents mimic or enhance ischaemic preconditioning.  Isoflurane, 
enflurane, halothane, sevoflurane and desflurane have all been implicated in 
various animal models, through their activation of ATP-sensitive potassium 
channels (KATP) (Zaugg et al. 2003).  Perioperative opioid use was also restricted 
due to its indirect activation of Protein Kinase C, a known mediator in ischaemic 
preconditioning (Schultz et al. 1996; Zaugg et al. 2003).  
 
Heart rate, oxygen saturation, respiratory rate, end-tidal CO2 and rectal 
temperature were all monitored during surgery (Surgivet Monitor, Model 
V9212AR, Smiths Medical, Wisconsin, USA).  Rectal temperature was kept 
within the normal range for the pig (38 – 390C).  The animal was kept warm by 
ensuring the operating room was at a constant 220C, as well as by using a heated 
blanket (Aquamatic K Thermia Heating Blanket, Cincinnati, Ohio, USA) and 
infrared heat lamp. 
 
2.3.3 Recovery 
During the final hour of the ischaemic insult the animal was weaned from the 
pentobarbitone infusion by reducing the infusion dose by 50% and then stopping 
the infusion following closure of skin wounds.  This facilitated an earlier 
recovery of the animal following the surgery.  Following completion of surgery, 
 68 
inhaled N2O was stopped and the ventilatory rate reduced to allow end-tidal CO2 
to rise and stimulate spontaneous respiration.  Mucous secretions were cleared 
from the oropharynx by suction catheter as required and the animal was 
extubated once appropriate oro-pharyngeal reflexes were present, the i.v. cannula 
was removed at this stage.  The animal remained in the operating room until 
sufficient oxygen saturation was maintained on room air, and then was returned 
to a warm pen in the animal holding room with food and water.  Animals were 
reviewed bi-daily and given analgesia as required. 
 
2.3.4 Sacrifice 
 
Following the completion of the surgical protocol and harvesting of bilateral LD 
muscle flaps under general anaesthesia, animals were euthanised with an 
overdose of sodium pentobarbitol (10ml (2.4g) Euthanyl; Bimeda Animal Health 
Ltd., Cambridge, ON, Canada).  Animals were bagged and placed in a 
refrigerated locker until collection for incineration. 
 
 
2.4 Surgical Protocol 
 
2.4.1 Raising of LD Muscle Flaps 
The animal was placed in the left or right lateral decubitus position and one of 
the flanks prepped with Betadine solution (10% povidone-iodine) and draped 
with sterile cloth drapes followed by skin markings for the incision.  The skin 
incision was designed using the forelimb shoulder and scapular tips as markers 
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and a 15cm long trap-door incision drawn to ensure a 13x8cm flap could be 
raised under direct vision (Figure 2.2). Skin incisions were made on each flank 
using a scapula and the trap-door skin flap was raised with the pannniculus 
carnosus en-bloc, exposing the LD muscle (Figure 2.3).  A 13x8cm flap was 
marked on the muscle, measuring 1cm from the ventral edge of the muscle.  The 
LD muscle was then raised using knife and bipolar diathermy (Pfizer Valleylab 
Force 2 Electrosurgical Generator, New York, USA) from distal to proximal, 
with preservation of the thoracodorsal pedicle on the underside of the flap 
(Figure 2.4).   
 
Dissection was performed under loupe vision into the axilla and then the flap 
was denervated by dissection of the thoracodorsal nerve from the pedicle and 
excising a section of it (Figure 2.5).  This denervation was performed to prevent 
painful muscle contractions during the 48-hour recovery period as well as acting 
as a surgical sympathectomy to reduced any neural influences on the flap.  To 
support the flap and protect the thoracodorsal pedicle, the musculotendinous 
insertion was maintained and was ligated with a 1-0 silk tie to ensure the only 
blood supply to the flap was via the thoracodorsal pedicle.  The muscle flap was 
then sutured back in position with 3-0 vicryl and the skin closed with 3-0 nylon, 
leaving an axillary opening for access to the pedicle. 
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Figure 2.2.  The animal is draped with sterile green towels and the skin is 
prepped with 10% Betadine solution.  The LD muscle is palpated and skin 
incision marked.  Identical skin exposure was performed in every animal in the 
study. 
 
 
 
     
Figure 2.3.  Once the skin and pannniculus layer is reflected the dimensions of 
the 13 x 8cm LD muscle flap are marked and the flap raised with sharp 
dissection. 
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Figure 2.4.  The flap is mobilised onto the osseo-tendinous humeral insertion, 
exposing the thoracodorsal pedicle on the ventral surface of the muscle.  Note 
the thickness of the LD flap in this picture (approx. 1cm thick). 
 
    
Figure 2.5.  The thoracodorsal pedicle is skeletised to allow for robust clamping 
of the artery and venae commitantes.  The thoracodorsal nerve is divided to 
denervate the flap (sympathetic denervation).  This also reduces painful 
contractions of the muscle for the animal postoperatively and mirrors the 
procedure of autogenous transfer in humans. 
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2.4.2 Global Ischaemia of LD Muscle Flaps 
Once bilateral LD flaps have been raised and sutured back in position, the pig 
was positioned prone on the operating table and the muscle flaps allowed to 
equilibrate for 15 minutes.  Following this, two microvascular arterial clamps (2 
x 8 mm; Weck) were applied to the pedicle to occlude circulation and render the 
flap globally ischaemic (Figure 2.6).  The animal was then placed prone again 
for the duration of the standard 4-hour ischaemic insult. Intravenous injection of 
Fluorescine dye (15 mg/kg; Sigma Chemical Co., Oakville, ON, Canada) was 
performed following placement of the vascular clamps.  Global flap ischaemia 
was confirmed bilaterally by observation of a lack of green fluorescence (Figure 
2.7) in the LD flaps under an ultraviolet Wood’s lamp (Mineralight lamp, Model 
UVG – 11, Ultraviolet Products Inc., San Gabriel, CA, USA).  Operating room 
temperature (220C) and rectal temperature (38 - 390C) were monitored during the 
4-hour ischaemic insult. 
 
Reperfusion of the LD muscles, after removal of vascular clamps, was confirmed 
by the hyperaemic response of the reperfused muscle flap and/or a second 
intravenous injection of Fluorescine and swift return of yellow fluorescence to 
the LD flaps.  The remaining axillary skin incisions were then closed with 3-0 
nylon and the pig allowed to recover from anaesthesia. 
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Figure 2.6.  Two 8mm Weck clamps were used to ensure cessation of blood-flow 
across the pedicle.  A 1-0 silk ligation suture was tied around the musculo-
tendinous insertion to insure that there was no collateral blood flow into the 
muscle.  Clamps were left in place for a period of 4 hours to simulate a global 
ischaemic insult of the LD muscle flap.  
 
        
Figure 2.7.  Intravenous injection of Fluorescine dye (15 mg/kg) was performed 
following placement of the clamps.  The bilaterally clamped LD flaps were then 
inspected under an ultraviolet Wood’s lamp.  Absence of fluorescence in the flap 
indicated global ischaemia. 
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The ischaemic insult, induced by the temporary clamping of the thoracodorsal 
pedicle, was for a period of 4 hours.  Previous work in this laboratory by Morris 
et al has looked at incremental time periods of ischaemic insult by this method of 
pedicle clamping in the porcine LD flap model (Morris et al. 1993). They found 
that when pedicles are clamped for greater than 4 hours there is risk of 
irreversible endothelial damage from clamp pressure resulting in thrombosis and 
immediate necrosis of the flap.  Previous experiments using a 4-hour ischaemic 
insult have resulted in muscle infarction control rates of 40-50% (Pang et al. 
1995; Hopper et al. 2000; Addison et al. 2003).  In order to standardise our 
results in line with previous research on this model, we chose an ischaemic 
interval of 4 hours. 
 
 
2.4.3 Nicorandil Injection 
 
Nicorandil (Chugai Pharmaceutical, Tokyo, Japan) was stored in powder form 
and dissolved in normal saline prior to injection.  The animal was brought to the 
anaesthetic room and given an intramuscular dose of Akmezine 1ml / 6kg animal 
weight (Ketamine, Acepromazine, Atropine) as described earlier.  I.v. 
cannulation of an ear vein was performed with the animal under sedation and 
masked with O2 and N20 (1:1 volume). Intravenous injection of Nicorandil was 
carried out via injection of the dissolved drug into a 125ml bag of normal saline 
(100 µg/kg bolus injection, followed by 30 µg.kg-1.min-1).   The bag was given 
over a period of 60 min resulting in a total of 3 mg/kg infused.  The animal’s 
heart rate and O2 saturation was monitored throughout the infusion. 
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2.4.4 Measurement of Arterial Blood Pressure 
 
Following the harvesting of LD muscle flaps and prior to animal euthanisation, 
invasive measurement of arterial blood pressure was performed over a 90 min 
period.  The animal was placed in the supine position and the right groin 
explored.  The right femoral artery was exposed by surgical dissection and 
cannulated with a polyethylene cannula (Becton Dickinson, Franklin Lakes, NJ, 
USA) under direct vision.  A pressure transducer was connected and calibrated 
to give a Mean Arterial Pressure (MAP) trace on the monitor (Hewlett Packard 
78534A, Andover, USA) and allowed to equilibrate for 5 min.  Nicorandil was 
then given as before by i.v. injection via ear vein cannulation over a period of 60 
minutes.  The MAP was recorded at 10-minute intervals throughout this period, 
as well as for 30 minutes after the infusion.  The animal was maintained under 
general anaesthesia as before on an infusion of normal saline (2ml/min) 
containing pentobarbitone sodium (0.5 – 1.0 ml/kg/min). 
 
 
2.4.5 Assessment of LD Muscle Viability 
 
Following 48 hours of reperfusion, animals were returned to the operating room 
and anaesthetised and intubated as before.  Bilateral flank incisions were 
reopened and LD flaps harvested.  The LD muscle flaps were then sectioned into 
thirteen 1x8 cm strips.  These strips were then incubated in Nitroblue tetrazolium 
(Sigma Chemical Co., Oakville, ON, Canada) dye for 30 minutes at 220C. 
Nitroblue tetrazolium (NBT) is made up using 200 mg of tetrazolium in 400 ml 
of 0.2% Tris buffer at pH 7.4 and temperature 22 ˚C to give a final concentration 
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of 0.5 mg/ml.  Tissue hydrogenases in viable muscle reduce NBT salts to an 
intense blue formazine stain.  Therefore viable muscle in each strip stained blue 
while the necrotic areas remained pink in colour (Figure 2.8) (Morris et al. 
1993).  
 
The muscle strips were then removed from the NBT solution, blotted and laid 
out in cross-section on white card and a digital photograph taken (Sony 
Cybershot DSC-P9).  All pictures were taken with the same camera under the 
same lighting conditions.  Computer planimetry with digital imaging software 
(Adobe Photoshop CS) was used to map out the necrotic and viable areas and 
therefore calculate a percentage muscle infarction for each respective muscle 
flap.  This method has been well established in our lab, (Addison et al. 2003; 
Moses et al. 2005; McAllister et al. 2008) and other labs (Labbe et al. 1988; 
Galie et al. 1995), and has been found to correlate closely with the previously 
published template method (Morris et al. 1993).  Other studies have looked at the 
accuracy of NBT reduction in the assessment of skeletal muscle viability.  Labbe 
et al (Labbe et al. 1988) demonstrated accuracy of NBT reduction to assess the 
necrosis rate of bilateral canine gracilis skeletal muscle flaps after 48 hours 
reperfusion.  Electron microscopy was employed to confirm the validity of this 
method and the same method of computer planimetry was used to estimate the 
percentage necrosis. 
 
Previous work in our lab (Pang et al. 1995) has demonstrated that 8x13 cm LD 
skeletal muscle flaps exhibit no necrosis when they were incubated in NBT, 
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prior to any ischaemic insult.  Therefore a non-ischaemic control group was not 
planned for this thesis project to avoid unnecessary death of animals. 
 
   
 
 
Figure 2.8.  Demonstration of the pattern of skeletal muscle infarction in the 
porcine latissimus dorsi (LD) muscle flaps subjected to 4hr ischaemia and 48hr 
reperfusion.  Each muscle flap is cut transversely into thirteen 8 x 1cm segments, 
which were incubated in 0.5 mg/ml nitroblue tetrozolium dye solution at 220C 
for 30 mins.  The viable areas are stained dark blue, and the non-viable 
(necrotic) areas remain red in colour.  The flap on the left is from an ischaemic 
control animal and the flap on the right is from a Nicorandil pre-treated animal. 
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2.5 Laboratory Analyses 
 
2.5.1 Collection & Preparation of Muscle Biopsies 
 
For the m[Ca2+], ATP and MPO assays, a series of muscle biopsies were taken (1 
x 1cm) with a scalpel, sequentially from the dorsal (thick) edge of each LD 
muscle, starting 1cm proximal to the free distal edge of the flap, and moving 
proximally, (i.e. taken at 7, 6, 5 and 4cm from the proximal flap edge.  The 
decision to take biopsies from the thicker dorsal edge of the muscle flap is due to 
the fact that skeletal muscle in this area is subjected to maximal reperfusion 
induced muscle necrosis (see Figure 2.8).  Biopsies were taken immediately 
before; at 2h and 4h ischaemia; and then finally at 1h reperfusion.  Each muscle 
biopsy specimen was rinsed with cold (40C) isotonic saline.  Part of the biopsy 
was then frozen in liquid nitrogen and stored at -80 0C in order to carry out ATP 
and MPO assays at a later stage.  The remaining fresh tissue was processed 
immediately to assay the mitochondrial free Calcium content (m[Ca2+]). 
 
 
2.5.2 Measurement of Mitochondrial Free Calcium Content    
(m[Ca2+]) 
 
The method of isolating mitochondria from fresh tissue by differential 
centrifugation, was adapted from that published by Rousou and colleagues 
(Rousou et al. 2004). Each muscle biopsy was cut into small pieces with a 
scalpel, washed with cold (4 ˚C) isotonic saline and placed in 7 ml of cold Buffer 
A (4 ˚C), containing 300 mM sucrose, 10 mM K+-Hepes, (pH 7.2) and 1 mM K+-
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EGTA (pH 8.0). The tissue was then homogenised (Polytronic PT-10-35, 
Kinematic, ON, Canada) for 40 sec at 4 ˚C. Nagarse (0.2 mg/ml homogenate; 
Sigma Chemical Co., Oakville, ON, Canada) was added to the homogenate. This 
was then incubated on ice for 10 min, and subsequently centrifuged at 750 g for 
6 min. The supernatant was saved, bovine serum albumin (BSA) was added (1 
mg/ml), and this was re-centrifuged at 750 g at 4 ˚C for 6 min. The pellet was 
discarded, and the resulting supernatant was centrifuged at 9000 g at 4 ˚C for 10 
min at ˚C. The mitochondrial pellet was saved and resuspended in 7 ml cold 
Buffer A (4 ˚C) containing 1 mg/ml BSA, then centrifuged twice at 9000 g at 4 
˚C for 10 min.  The final pellet was suspended in 0.2 ml of respiration medium, 
containing 250 mM sucrose, 2 mM KH2PO4, 10 mM MgCl2, 20 mM K+-Hepes 
(pH 7.2) and 0.5 mM EGTA (pH 8.0) at 4 ˚C. 
 
The suspension of mitochondrial pellet was used for assay of free (m[Ca2+]), 
which was determined using a spectrofluoresence technique. The 0.2 ml of pellet 
suspension was added to 1.8 ml of loading buffer containing 140 mM NaCl, 5 
mM KCl, 5.6 mM glucose and 5 mM HEPES (pH 7.4), and then loaded with 1 
µM Fura-2-AM (Molecular Probes, Eugene, OR, USA) in DMSO (final 
concentration 0.1%) and 0.006% Pluronic F-127 (Molecular Probes, Eugene, 
OR, USA) and incubated in a shaking bath for 15 min at 30 ˚C in the dark. This 
was then centrifuged at 9000 g for 10 min at 30 ˚C to pellet the mitochondria, 
and the mitochondrial pellet was re-suspended in 0.2 ml loading buffer and 
added to a black 96-well microplate (BD Biosciences, Mississauga, Ontario, 
Canada). Sample blanks received 0.1% (final concentration) DMSO as a vehicle 
only. This was read in a microplate reader (Spectra Max Gemini EM, Molecular 
Devices Corporation, Downington, PA, USA) at 340 and 380 nm (excitation) 
 80 
and 510 nm (emission). Calibration was performed using a calcium calibration 
kit and Fura-2 penta-potassium salt (Molecular Probes, Eugene, OR, USA). The 
amount of mitochondrial free Ca2+ was determined from the ratio of emission 
induced by the two excitation wavelengths. 
  
Mitochondrial protein content was determined by the Bradford method (Bio-Rad 
Life Sciences, Hercules, CA, USA). The Bradford method for protein 
determination utilises a dye (Coumassie® Brilliant Blue G-250), which, under 
acidic conditions, exists predominantly in the red cationic form. When the dye 
binds to protein, it is converted to a stable blue form, with a shift in absorbance 
maximum from 465 nm to 595 nm. 
 
The mitochondrial protein for assay was added to a 96-well microplate (BD 
Biosciences, Mississauga, Ontario, Canada). Sample blanks received 10 mg/ml  
(final concentration) bovine serum albumin as a vehicle only. This was read in a 
microplate reader (Spectra Max Gemini EM, Molecular Devices Corporation, 
Downington, PA, USA) at 595 nm (absorbance). Calibration was performed 
using bovine serum albumin standards (Bio-Rad Life Sciences, Hercules, CA, 
USA). The free m[Ca2+] was expressed as nanomol/mg mitochondrial protein. 
 
 
2.5.3 Measurement of Adenosine Triphosphate (ATP) Content 
 
The muscle biopsies (~200 mg), previously stored at -800C, were homogenised 
in 2 ml of cold (4 ˚C) tricholoroacetic acid (2.5 % vol/vol) and the homogenate 
was centrifuged for 10 min at 1000 g at 4 ˚C. The supernatant was neutralised 
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with 1 M Tris base (120 µl/ml supernatant), and was then used for assay of ATP 
content using a FL-AA bioluminescent assay kit (Sigma, Oakville, ON, Canada).  
 
The kit can be used for the quantitative analysis of ATP within the range 2 x 10-
12 to 8 x 10-5 ml/litre. The following reactions occur: 
 
                               
ATP + Luciferin Adenyl-luciferin + Ppi 
 
Adenyl-luciferin + O2 Oxyluciferin + AMP + CO2 + Light 
 
The light emission from this reaction is determined using a luminometer and the 
ATP concentration is measured from standard curves prepared from solutions of 
known ATP concentration provided with the assay kit. The pellet was neutralised 
with 1 ml of 0.5 M NaOH and the protein content was determined by the 
Bradford method (Bio-Rad Life Sciences, Hercules, CA, USA), as described 
before. The muscle content of ATP was expressed as micromoles per gram of 
protein (McAllister et al. 2008). 
 
 
2.5.4 Measurement of Myeloperoxidase (MPO) Activity 
 
Myeloperoxidase is a lysosomal proteinase, prevalent in neutrophil granulocytes.  
It has been well validated as a marker of neutrophil accumulation in both 
Firefy Luciferase 
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myocardial (Jordan et al. 1999; Wang et al. 1999) and skeletal muscle (Pang et 
al. 1997; Hopper et al. 2000). 
Frozen muscle samples (~200 mg) were homogenised (Polytronic PT-10-35, 
Kinematic, ON, Canada) in 2 ml of cold Solution A (4 ˚C), containing 100 mM 
NaCl, 20 mM NaH2PO4 and 15 mM EDTA (pH 4.7) for 30 sec at 4 ˚C. This was 
then centrifuged at 12000 g for 20 min at 4 ˚C. The supernatant was discarded, 
and the pellet homogenised for 45 sec in 2 ml of ice-cold solution B, containing 
50 mM KH2PO4 and 0.5% (by volume) cTAB (hexadecyltrimethylammonium 
bromide), at pH 5.4. The homogenate was sonicated for 10 sec on ice, and then 
underwent three freeze-thaw cycles in liquid nitrogen, before being centrifuged 
at 12 000 g for 20 min at ˚C. The resulting supernatant was collected and assayed 
for neutrophilic MPO activity using a spectrophotometric technique previously 
described by us (Pang et al. 1995; Pang et al. 1997; Pang et al. 1997; Hopper et 
al. 2000; Moses et al. 2005).   
 
The enzyme activity was evaluated by measuring the H2O2-dependent oxidation 
of 3,3’,5,5’-tetramethylbenzidine (TMB). A spectrophotometer (Beckman 
DU50, Beckman Coulter Canada Inc., Mississauga, ON, Canada) was used to 
measure the generation of oxidised TMB at 655 nm and 37 ˚C. The reaction 
mixture contained 10 µl of supernatant, 1.6 mM TMB, 0.3 mM H2O2, 80 mM 
sodium phosphate buffer (pH 5.4), 8% N,N-dimethyl formanide, and 40% 
Dulbecco’s phosphate-buffer saline in a total volume of 550 µl. MPO activity 
was expressed as initial velocity of absorbance increase at 655 nm per minute 
per gram wet tissue.     One unit of enzyme activity was defined as the amount of 
MPO that produced an absorbance change of 1.0 optical density unitmin-1g wet 
muscle-1 at 37 ˚C. 
 83 
2.5.5 Biochemicals 
 
All chemical reagents and assay kits were purchased from Sigma Chemical Co. 
Ltd. (Oakville, ON, Canada), unless otherwise stated.  Purified water from a 
Milli-Q Water System (Bedford, MA, USA) was used to make all solutions and 
standards. Nicorandil (N-(2-hydroxyethyl)-nicotinamide nitrate) was a gift from 
Chugai Pharmaceutical, Tokyo, Japan.  1-[[5-[2-(5-Chloro-0-anisamido)ethyl]-2-
methoxyphenyl]sulphonyl]-3-methyl-thiourea sodium salt (HMR-1098, Aventis 
Pharma) was dissolved in 10 ml of saline (0.9%).  5-Hydroxydecanoate sodium 
(5-HD; 10mg/kg) was dissolved in 10 ml of saline (0.9%).  We chose a dose of 6 
mg/kg for HMR-1098 and 10 mg/kg for 5-HD, following the published 
information by Moses et al (Moses et al. 2005).  All drug solutions were 
prepared not more than 30 min before intravenous injection. 
 
 
 
2.6 Experimental Protocol 
 
2.6.1 Study 1:  To investigate the dose-response effect of Nicorandil-
induced late phase IPC when given 24 hours before instigation of I/R 
injury in porcine LD muscle flaps. 
 
Incremental concentrations of Nicorandil (0.1, 0.3, 1, 1.5, 2 and 3 mg/kg) were 
given intravenously 24 hours before the onset of 4 hours muscle ischaemia, 
followed by 48 hours reperfusion. After 48 hours reperfusion, muscle infarction 
was assessed by nitroblue tetrazolium reduction technique, as described earlier. 
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Figure 2.9.  Investigating the dose-response effect of Nicorandil (Study 1).  Pigs 
received a saline infusion (ischaemic control) or saline containing 0.1 – 3 mg/kg 
Nicorandil (treatment group) over a 60-minute period, 24 hours prior to muscle 
flaps subjected to 4 hours sustained ischaemia and 48 hours reperfusion.  The 
illustration of remote delayed IPC is for comparative purposes only. 
 
 
 
2.6.2 Study 2:  To investigate the effect of intravenous Nicorandil on mean 
arterial blood pressure (MAP) in the porcine model. 
 
The aim of this experiment was to investigate the effects of intravenous 
Nicorandil on the pig’s MAP while under anaesthesia.  From the results of Study 
1, an optimal dose of Nicorandil (3 mg/kg) was chosen.  While under 
anaesthesia, animals had their right femoral artery cannulated and MAP 
monitored for a 90 min period following the injection of saline alone or saline 
containing Nicorandil (3 mg/kg) over a period of 60 min. 
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Figure 2.10.  The effect of intravenous Nicorandil pretreatment on mean arterial 
pressure (MAP).  MAP was measured via cannulation of the right femoral artery 
under general anaesthesia, for a 90-min period.  Saline or saline containing 3 
mg/kg Nicorandil was infused over 60 min followed by 30 min saline infusion.  
MAP (mmHg) was recorded in 10-min intervals. 
 
 
 
2.6.3 Study 3:  To investigate the efficacy of Nicorandil in induction of late 
IPC for uninterrupted perioperative protection of skeletal muscle 
against I/R injury in porcine LD muscle flaps. 
 
This study was designed to investigate the efficacy of Nicorandil in inducing late 
IPC, when given at a series of time points before the onset of 4 hours ischaemia, 
followed by 48 hours reperfusion.  Intravenous Nicorandil was prepared as 
described earlier and given to the animal under sedation, over a period of 60 min.  
Incremental time periods between Nicorandil injection and the onset of 
ischaemic insult were as follows: 0, 4, 8, 12, 24, 48, 72 and 96 hr.  Following 4 
hr ischaemia and 48 hr reperfusion, LD muscle infarction was assessed as before. 
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Figure 2.11.  The efficacy and time-course of Nicorandil-induced 
preconditioning.  Nicorandil (3 mg/kg) was administered intravenously 0, 4, 8, 
12, 24, 48, 72 and 96 hours before LD muscle flaps were subjected to 4 hours 
sustained ischaemia and 48 hours reperfusion.  All muscle flaps were then 
harvested and assessed for viability. 
 
 
 
2.6.4 Study 4: To investigate the effect of Nicorandil-induced late IPC on 
muscle content of m[Ca2+], ATP and MPO activity in porcine LD 
muscle flaps subjected to 4 hours ischaemia and 48 hours 
reperfusion. 
 
In this study, animals were assigned to a control or treatment group.  The control 
group received intravenous injection of saline and the treatment group, injection 
of Nicorandil (3mg/kg), 24 hr before the onset of 4 hr sustained ischaemia.  
Muscle biopsies (1x1 cm) were taken from both LD muscle flaps immediately 
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before sustained ischaemia; at 2 hr and 4 hr ischaemia; and at 1 hr reperfusion.  
Fresh muscle biopsies were processed for assay of m[Ca2+].  Remaining tissue 
was frozen at -80˚C for assay of ATP content and MPO activity. 
 
 
 
 
Figure 2.12.  Animals were assigned to saline ischaemic control or Nicorandil 
treatment group.  After a 24-hour delay LD flaps were raised and subjected to 4 
hours ischaemia and 48 hours reperfusion.  Skeletal muscle biopsies were taken 
at 0hr, 2hr and 4hr of ischaemia; and at 1hr reperfusion ( ).  Biopsies were 
assayed for m[Ca2+], ATP content and MPO activity. 
 
 
 
2.6.5 Study 5: To investigate the role of sarcolemmal K+ (sKATP) channels 
in the trigger mechanism of Nicorandil-induced late IPC. 
 
Study 5 was designed to demonstrate the involvement of sKATP channels in the 
trigger mechanism of Nicorandil-induced late IPC. Animals were assigned to an 
ischaemic control and seven treatment groups: 1) Saline; 2) Nicorandil; 3) HMR-
1098 + Nicorandil; 4) 5-HD + Nicorandil; 5) Glibenclamide + Nicorandil; 6) 
HMR-1098 + Saline; 7) 5-HD + Saline and 8) Glibenclamide + Saline. 
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The sKATP channel inhibitor HMR-1098, the mKATP channel inhibitor 5-HD or 
the non-specific KATP inhibitor was injected intravenously 10min before 
administration of saline or saline containing Nicorandil (3 mg/kg), 24hr prior to 
subjecting LD muscle flaps to 4hr ischaemia and 48hr reperfusion. 
 
 
 
 
 
 
Figure 2.13.  Protocol for investigation of the trigger mechanism in Nicorandil-
induced late protection of skeletal muscle against ischaemia / reperfusion 
injury. There were 4-5 pigs with bilateral LD muscle flaps in each group. All the 
LD muscle flaps in the control and treatment groups were subjected to 4h 
ischaemia and 48h reperfusion. Intravenous administration of saline or saline 
containing Nicorandil (3 mg/kg) was performed 24h before 4h ischaemia (i.e. 
late protection). The sarcolemmal KATP (sKATP) channel inhibitor HMR 1098 
(HMR; 6 mg/kg), the mitochondrial KATP (mKATP) channel inhibitor 5-
hydroxydecanate (5-HD; 10 mg/kg), and the nonspecific KATP channel inhibitor 
glibenclamide (Glib; 1 mg/kg) were injected intravenously at 10 min before 
intravenous injection of saline or saline containing Nicorandil. Muscle 
infarction was assessed after 48h reperfusion, using the nitroblue tetrazolium 
dye staining technique.  
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2.6.6 Study 6: To investigate the role of mitochondrial K+ (mKATP) 
channels in the effector mechanism of Nicorandil-induced late IPC. 
 
Study 6 was designed to demonstrate the involvement of mKATP channels in the 
effector mechanism of Nicorandil-induced late IPC. Animals were assigned to an 
ischaemic control and seven treatment groups: 1) Saline; 2) Nicorandil; 3) 
Nicorandil + HMR-1098; 4) Nicorandil + 5-HD; 5) Nicorandil + Glibenclamide; 
6) Saline + HMR-1098; 7) Saline + 5-HD and 8) Saline + Glibenclamide. 
 
In Study 6, saline or saline containing Nicorandil (3 mg/kg) was administered, 
24hr before subjecting LD muscle flaps to 4hr ischaemia and 48hr reperfusion. 
10min before the onset of 4hr ischaemia, the sKATP channel inhibitor HMR-
1098, the mKATP channel inhibitor 5-HD or the non-specific KATP channel 
inhibitor was injected intravenously as a bolus. 
 
 
 
 
 
 
Figure 2.14. Protocol for investigation of the mediator mechanism in 
Nicorandil-induced late protection of skeletal muscle against ischaemia / 
reperfusion injury. The protocol was the same as the protocol for investigation 
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of the trigger mechanism in Figure 2.9 except that HMR-1098 (sKATP channel 
inhibitor), 5-HD (mKATP channel inhibitor) and Glibenclamide (non-specific 
KATP channel inhibitor) were injected intravenously at 24h after intravenous 
injection of saline or saline containing Nicorandil (3 mg/kg). 
 
 
 
 
 
 
2.7 Statistical Analysis 
 
All values are expressed as means +/- Standard Error of the Mean (SEM) unless 
otherwise stated.  The number of observations in each study is described in the 
legends of the figures and tables.  In studies 1-3, 5 and 6 mean values at each 
time point were compared using one-way Analysis of Variance (ANOVA) and 
Newman-Keuls multiple comparison test.  For study 4 two-way ANOVA and 
students t-test were employed.  Statistical significance was set at P < 0.05 for all 
tests. All statistical analyses were performed using the biostatistics software 
package SPSS (Chicago, Illinois 60606). 
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3.0  RESULTS 
 
3.1 Animal Demographics 
 
A total of 109 castrated male Yorkshire pigs were used in the following 
experiments, including 9 pilot controls used to gain consistency in the 
experimental model.  The mean animal weight was 17.9kg (range 15 – 24kg; 
stdev 1.4kg).  There were 4 premature animal deaths: 2 on-table intra-operative 
deaths; 1 animal required on-table euthanasia due to ongoing metabolic acidosis; 
1 animal died on the 1st post-operative day of respiratory complications. 
   
There were no significant differences between treatment groups when animal 
weight, duration of operation, or recovery time was taken into account. 
 
 
3.2  Study 1:  To investigate the dose-response effect of Nicorandil-
induced   late phase IPC when given 24 hours before instigation of I/R 
injury in   porcine LD muscle flaps. 
 
In this preliminary study we performed a series of dosage experiments to find the 
optimum dose of Nicorandil to effectively protect the LD muscle flap from I/R 
injury. 
We looked at the dosages other investigators were using in large animal studies, 
such as Tang et al with rabbits (Tang et al. 2004); Mizumura et al with dogs 
(Mizumura et al. 1996) and Galie et al in pigs (Galie et al. 1995). 
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As described earlier, incremental concentrations of Nicorandil (0.1 mg/kg to 3 
mg/kg) were injected intravenously with an initial bolus injection followed by a 
60 min infusion.  24 hours later, the LD muscle flaps were subjected to 4 hours 
global ischaemia followed by 48 hours reperfusion. After 48 hours reperfusion, 
muscle infarction was assessed by nitroblue tetrazolium reduction technique. 
 
 
No. of pigs Control 0.1 - 0.3mg/kg 1-2mg/kg 3mg/kg 
1 55 33 55 28 
 41 - 43 15 
2 40 36 27 33 
 36 37 24 29 
3 37 26 41 14 
 45 22 30 10 
4 36 21 27 34 
 47 25 29 10 
5 39 46 24 20 
 41 39 17 22 
6   27  
   17  
Mean 41.7 31.7 30.1 21.5 
SEM 1.9 2.9 3.2 2.9 
 
Table 3.1.  Incremental dosages of i.v. Nicorandil (mg/kg) given 24 hr before 
ischaemic insult.  Flap necrosis expressed as % infarction, mean and standard 
error of the mean (SEM), n = 5-6 pigs. 
 
 
We observed a dose-dependent effect of i.v. Nicorandil, whereby increasing the 
concentration resulted in a reduction in percentage infarction of LD muscle flaps, 
i.e. an increase in infarct protection of the skeletal muscle (Figure 3.1).  
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Figure 3.1. Dose-response effect of intravenous administration of Nicorandil for 
induction of late phase infarct protection in skeletal muscle. There were between 
5 and 6 pigs with bilateral LD muscle flaps in each group. All LD muscle flaps 
were subjected to 4h ischaemia starting at 24h after intravenous administration 
of saline (control) or saline containing Nicorandil. Muscle infarction was 
assessed after 48h reperfusion. Means with an asterisk are similar and are 
significantly different from the control (oneway ANOVA and Newman Keuls 
multiple range test; *p < 0.05). 
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3.3  Study 2: To investigate the effect of intravenous Nicorandil on mean 
arterial blood pressure (MAP) in the porcine model. 
 
Following the preliminary dosage study we chose an optimum concentration of 
3mg/kg i.v. Nicorandil.  We investigated the effect of this concentration on 
changes in mean arterial pressure (MAP) following i.v. infusion in the porcine 
model. 
 
 
Time 
(min) 0 10 20 30 40 50 60 70 80 
 
90 
1 83 73 78 75 74 72 72 72 72 72 
2 71 69 68 71 73 73 75 75 74 75 
3 87 88 88 90 92 93 93 93 93 93 
Mean 80.3 76.7 78 78.7 79.7 79.3 80 80 79.7 80 
SEM 4.8 5.8 5.8 5.8 6.2 6.8 6.6 6.6 6.7    6.6 
 
Table 3.2.  Mean Arterial Pressure (mmHg) for saline control group, n= 3 pigs 
 
Time 
(min) 0 10 20 30 40 50 60 70 80 90 
1 58 40 43 42 22 19 26 84 62 67 
2 92 42 41 44 68 65 62 58 80 90 
3 59 17 17 33 55 54 53 42 49 56 
4 105 89 60 70 52 47 42 49 - - 
5 90 60 58 60 51 53 53 - - - 
6 99 87 63 57 66 65 59 57 74 - 
Mean 82.8 63.6 55 55.2 55.6 53.3 52.6 58 66.2 71 
SEM 5.1 7.9 5.9 4.3 5.5 5.5 4.6 7.1 6.9 10.0 
 
Table 3.3.  Mean Arterial Pressure (mmHg) for Nicorandil (3mg/kg) treatment 
group, n= 6 pigs. 
 
As described earlier, MAP was measured for 90 mins in anaesthetised animals 
via a cannula placed in the right femoral artery.  Nicorandil (3mg/kg) was 
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injected as an infusion over the first 60min with an infusion of normal saline 
(2ml/min), continuing for another 30min.  During the first 60 minutes of i.v. 
Nicorandil infusion there was a significant reduction in MAP when compared to 
the saline-infused animals.  However, the MAP normalised within 30 min of the 
end of the Nicorandil infusion (Figure 3.2). 
 
 
 
 
Figure 3.2.  Change in Mean Arterial Pressure (MAP) after intravenous 
administration of Nicorandil (3mg/kg).  The control and Nicorandil treatment 
groups received intravenous infusion of saline and saline containing Nicorandil 
(3mg/kg), respectively.  Values are mean +/- SEM; n = 5 pigs.  Comparisons at 
each timepoint were calculated using one-way ANOVA and Newman Keuls 
multiple range test; p < 0.05. 
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3.4 Study 3: To investigate the efficacy of Nicorandil in induction of late-
phase IPC for uninterrupted perioperative protection of skeletal 
muscle against I/R injury in porcine LD muscle flaps. 
 
Incremental time periods between Nicorandil injection (3mg/kg) and the onset of 
ischaemic insult were as follows: 0, 4, 8, 12, 24, 48, 72 and 96 hr.  Following 4 
hr ischaemia and 48 hr reperfusion, LD muscle infarction was assessed as before. 
 
 
n = control 0hr 4hr 8hr 12hr 24hr 48hr 72hr 96hr 
1 34 33 13 39 26 23 33 27 57 
 41 30 37 51 33 17 15 34 55 
2 39 22 21 33 52 26 20 23 25 
 55 29 21 28 61 16 29 18 38 
3 41 27 31 39 30 27 24 33 34 
 39 28 24 53 43 28 22 29 44 
4 35 31 21 44 53 15 31 28 54 
 36 19 24 - 61 18 27 - 17 
5 37  24   14    
 45     33    
Mean 40.2 27.4 24 41 44.9 22.4 25.1 28.5 43.9 
SEM 1.9 1.6 2.2 3.4 4.9 2.0 2.1 2.1 4.6 
 
 
Table 3.4. Timecourse of Nicorandil injection (3mg/kg) prior to ischaemic insult.  
Flap necrosis expressed as % infarction, mean and standard error of the mean 
(SEM), n = 4-5 pigs. 
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There was 40 +/- 2% infarction rate in control LD muscle flaps subjected to 4hr 
ischaemia and 48hr reperfusion.  Ischaemic preconditioning with i.v. Nicorandil 
(3mg/kg) given at 0hr and 4hr before instigation of ischaemic insult significantly 
reduced the infarct size to 27.3 +/- 1% and 24.0 +/- 2 % respectively (Figure 3).  
However this Nicorandil-induced infarct protective effect waned, resulting in the 
muscle infarction rate increasing to 41.0 +/- 3% at 8hr and 44.8 +/- 5% at 12hr.  
These are similar rates of muscle infarction to the ischaemic control.  
Importantly, this “late phase” Nicorandil-induced infarct protective effect 
returned at 24hr and continued for another 48hr with infarction rates of 22.3 +/- 
2%, 25.1 +/- 2% and 28.5 +/- 2% at 24hr, 48hr and 72hr respectively.  When 
Nicorandil was given 96hr before the onset of 4hr ischaemia, the infarct 
protective effect was lost with an infarction rate of 44 +/- 6%, similar to the 
ischaemic control (Figure 3.3). 
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Figure 3.3. Induction of biphasic infarct protection in skeletal muscle by 
intravenous administration of Nicorandil.  There were 4 – 5 pigs with bilateral 
LD muscle flaps for each time point. All control and treatment LD muscle flaps 
were subjected to 4h of ischaemia and 48h of reperfusion. In Nicorandil 
treatment groups, 4h of sustained ischaemia started at 0, 4, 8, 12, 24, 48, 72, or 
96 hr after intravenous administration of Nicorandil.  Muscle infarction values 
are expressed as mean +/- SEM.  Means with an asterisk are similar and are 
significantly different from the rest of the means without an asterisk (oneway 
ANOVA and Newman Keuls multiple range test; *p < 0.05). 
 
 
3.5 Study 4: To investigate the effect of Nicorandil-induced late IPC on 
muscle content of m[Ca2+], ATP and MPO activity in porcine LD 
muscle flaps subjected to 4 hours ischaemia and 48 hours reperfusion. 
 
 
The ischaemic control group received intravenous injection of saline and the 
Nicorandil pre-treatment group, injection of Nicorandil (3mg/kg), 24 hr before 
the onset of 4 hr sustained ischaemia.  Muscle biopsies (1x1 cm) were taken 
from both LD muscle flaps immediately before sustained ischaemia; at 2 hr and 
4 hr ischaemia; and at 1 hr reperfusion.  Fresh muscle biopsies were processed 
for assay of mitochondrial free Ca2+ content (m[Ca2+]).  Remaining tissue was 
frozen at -80˚C for assay of ATP content and MPO activity. 
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Control pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 213.72 159.69 279.34 606.80 
2 213.89 187.75 265.29 865.16 
3 214.11 112.91 140.83 639.94 
4 213.94 208.76 201.85 995.78 
5 214.56 82.64 80.09 353.18 
6 213.91 229.58 326.77 987.93 
Mean 214.02 163.56 215.70 741.47 
SEM 0.12 23.18 37.87 103.27 
 
Table 3.5. Ischaemic control muscle biopsies for mitochondrial free calcium 
content at various time-points during ischaemia / reperfusion; n = 6 pigs. 
 
Nicorandil pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 213.97 181.01 239.63 553.38 
2 213.75 204.48 229.91 429.17 
3 213.67 123.89 177.72 660.71 
4 213.44 111.24 179.87 223.31 
5 213.98 80.04 234.50 312.40 
Mean 213.76 140.13 212.33 435.79 
 SEM 0.10 22.94 13.78 79.00 
  
Table 3.6.  Nicorandil pre-treatment muscle biopsies for mitochondrial free 
calcium content at various time-points during ischaemia / reperfusion; n = 5 
pigs. 
 
 
m[Ca2+] remained stable during the ischaemic insult, both in the control and 
treatment group, when measured at 0hr (213.8 / 214.0 nmol/mg); 2hr (140.1 / 
163.6 nmol/mg); and 4hr (212.3 / 215.7 nmol/mg).  However, at 1 hr reperfusion 
there was a significant rise in m[Ca2+] in both  the ischaemic control and 
Nicorandil pre-treatment groups (741.5 and 435.8 nmol/mg respectively), when 
compared to ischaemic groups. Further to this, in the Nicorandil pre-treatment 
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group, the rise in m[Ca2+] was significantly lower during the first hour of 
reperfusion, when compared to the control group, (p < 0.05) (Figure 3.4). 
 
 
 
 
Figure 3.4.  Mitochondrial Free Calcium content (m[Ca2+]) in porcine LD 
muscle flaps immediately before and at the end of 2hr and 4hr ischaemia and 
1hr reperfusion.  The control and treatment groups received intravenous 
infusion of saline and saline containing 3mg/kg Nicorandil, respectively.  
Infusions were given 24hr before the start of 4hr sustained ischaemia (late phase 
of protection).  Values are expressed as mean +/- SEM; n = 5 pigs.  Means with 
an asterisk are significantly different from the time-matched control (two-way 
ANOVA and t-test at each time-point; *p < 0.05). 
 
 
Adenosine Triphospate (ATP) content in LD muscle flaps was measured using a 
quantitative bioluminescent technique, as described earlier.  ATP content in the 
muscle biopsies showed a gradual reduction during the ischaemic insult with no 
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significant differences between control and treatment groups (30.8 +/- 1.7 vs. 
30.8 +/- 2.3 before ischaemia; 21.3 +/- 2.7 vs. 24.0 +/- 3.1 at 2hr ischaemia; 6.5 
+/- 1.2 vs. 9.8 +/- 2.7 at 4hr ischaemia mmol/g prot).  However, in the first hour 
of reperfusion there was a significant increase in muscle ATP content of the 
Nicorandil pre-treatment group, when compared to the control group (22.6 +/- 
2.0 vs. 12.4 +/- 1.8 mmol/g prot; p < 0.05) (Figure 3.5). 
 
 
Control pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 31.34 18.43 2.58 7.68 
2 38.48 13.97 2.90 9.22 
3 35.39 29.33 5.34 16.94 
4 29.27 24.12 8.79 14.58 
5 30.66 23.77 8.41 11.79 
6 19.88 18.62 10.76 14.00 
Mean 30.84 21.37 6.46 12.37 
SEM 1.68 2.73 1.17 1.79 
 
Table 3.7.  Ischaemic control muscle biopsies for muscle ATP content at various 
time-points during ischaemia / reperfusion; n = 6 pigs. 
 
Nicorandil pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 33.70 13.63 7.62 19.37 
2 33.90 24.54 14.72 24.86 
3 34.87 21.31 5.26 26.55 
4 22.24 29.98 17.75 25.91 
5 29.68 30.75 3.77 16.22 
Mean 30.88 24.04 9.82 22.58 
SEM 2.34 3.13 2.73 2.04 
 
Table 3.8.  Nicorandil pre-treatment muscle biopsies for muscle ATP content at 
various time-points during ischaemia / reperfusion; n = 5 pigs. 
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Figure 3.5.  Adenosine Triphosphate (ATP) content in porcine LD muscle flaps 
immediately before, and at the end of 2hr and 4hr ischaemia and at 1hr of 
reperfusion. The control and treatment groups received intravenous infusion of 
saline and saline containing 3mg/kg Nicorandil, respectively.  Infusions were 
given 24hr before the start of 4hr sustained ischaemia (late phase of protection).  
Values are expressed as mean +/- SEM; n = 5-6 pigs. Means with an asterisk 
are significantly different from the time-matched control (two-way ANOVA and 
t-test at each time-point; *p < 0.05). 
 
 
Myeloperoxidase (MPO) activity is a well-validated marker of neutrophil 
accumulation in skeletal muscle.  MPO was assayed in the skeletal muscle using 
a spectrophotometric technique.  During 0, 2 and 4hr of the ischaemic insult 
MPO levels remained low and negligible in both control and treatment groups 
(0.12 +/- 0.02 vs. 0.13 +/- 0.02 before ischaemia; 0.15 +/- 0.02 vs. 0.14 +/- 0.02 
at 2hr ischaemia; 0.19 +/- 0.04 vs. 0.13 +/- 0.02 at 4hr ischaemia).  During the 
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first hour of reperfusion there were significant increases in MPO activity of the 
control group (0.95 +/- 0.07) and the Nicorandil pre-treatment group (0.38 +/- 
0.08).  Further to this, the rise in MPO activity of the Nicorandil pre-treatment 
group was significantly less than the rise in the control group (0.38 +/- 0.08 vs. 
0.95 +/- 0.07 units/g wet muscle; p < 0.05) (Figure 3.6). 
 
 
Control pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 0.14 0.08 0.07 1.02 
2 0.11 0.15 0.24 1.04 
3 0.11 0.15 0.32 0.64 
4 - 0.20 0.20 1.01 
5 0.17 0.16 0.14 1.09 
Mean 0.13 0.15 0.20 0.96 
SEM 0.01 0.02 0.04 0.07 
 
Table 3.9.  Ischaemic control muscle biopsies for myeloperoxidase content at 
various time-points during ischaemia / reperfusion; n = 5 pigs. 
 
 
Nicorandil pre-ischaemia 2hr ischaemia 4hr ischaemia 1hr reperfusion 
1 0.10 0.15 0.19 0.62 
2 0.11 0.09 0.12 0.25 
3 0.11 0.18 0.10 0.42 
4 0.20 0.18 0.09 0.45 
5 0.12 0.11 0.14 0.13 
Mean 0.13 0.14 0.13 0.38 
SEM 0.02 0.02 0.02 0.08 
 
Table 3.10.  Nicorandil pre-treatment muscle biopsies for myeloperoxidase 
content at various time-points during ischaemia / reperfusion; n = 5 pigs. 
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Figure 3.6.  Muscle neutrophilic myeloperoxidase (MPO) activity in porcine LD 
muscle flaps immediately before, and at the end of 2hr and 4hr ischaemia and at 
1hr of reperfusion. The control and treatment groups received intravenous 
infusion of saline and saline containing 3mg/kg Nicorandil, respectively.  
Infusions were given 24hr before the start of 4hr sustained ischaemia (late phase 
of protection).  Values are expressed as mean +/- SEM; n = 5 pigs.  Means with 
an asterisk are significantly different from the time-matched control (two-way 
ANOVA and t-test at each time point; *p < 0.05). 
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3.6 Study 5: To investigate the role of ATP-sensitive K+ (KATP) channels in 
the trigger mechanism of Nicorandil-induced late IPC. 
 
Late phase ischaemic preconditioning was instigated by Nicorandil injection (3 
mg/kg) 24hr before subjecting LD muscle flaps to 4hr ischaemia and 48hr 
reperfusion.  The selective sarcolemmal KATP (sKATP) channel inhibitor HMR-
1098 (6 mg/kg) was injected as an intravenous bolus 10 minutes before 
Nicorandil injection.  HMR-1098 effectively blocked the preconditioning effect 
of Nicorandil, resulting in an infarction rate of 40.8 +/- 5%, similar to the 
ischaemic control rate of 46.1 +/- 3% (Figure 3.7). 
 
 
 
n = Control Nicorandil 5-HD + 
Nico. 
HMR + 
Nico. 
Gliben 
+ Nico. 
5-HD HMR-
1098 
Gliben 
1 55 17 16 25 39 40 27 46 
 37 26 20 34 40 45 33 40 
2 41 16 31 32 40 41 48 47 
 58 27 25 22 43 46 51 40 
3 41 28 25 64 41 43 49 40 
 45 15 21 63 42 46 42 43 
4 39 18 33 50 49 40 33 46 
 58 14 26 40 - 45 50 34 
5 47 33  27   49  
 40 29  35   55  
Mean 46.1 22.3 25.9 40.8 42.4 43.1 43.6 42.1 
SEM 2.6 2.2 2.0 4.8 1.2 1.3 4.2 2.2 
 
Table 3.11. The addition of pharmacological probes 5-HD, HMR-1098 and 
Glibenclamide before Nicorandil pre-treatment. Flap necrosis expressed as % 
infarction, mean and standard error of the mean (SEM), n = 4-5 pigs. 
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Further to this, the non-specific KATP channel inhibitor Glibenclamide (1 mg/kg) 
was injected as an intravenous bolus 10 minutes before Nicorandil injection.  
Glibenclamide also effectively blocked the preconditioning effect of Nicorandil, 
resulting in an infarction rate of 42.4 +/- 1% (Figure 3.7). 
 
However, the selective mitochondrial KATP (mKATP) channel inhibitor 5-HD (10 
mg/kg), when given 10min before Nicorandil injection, had no significant effect 
(25.9 +/- 2%) when compared to Nicorandil pre-treatment (22.3 +/- 2%).  The 
equivalent doses of 5-HD, HMR-1098 or Glibenclamide were also injected 10 
minutes before sham saline injection at 24hr before the onset of 4hr ischaemia 
and 48hr reperfusion.  This resulted in infarction rates of 43.6 +/- 1%, 43.7 +/- 
4% and 41.5 +/- 1% respectively, which are similar to the ischaemic control rate 
of 46.1 +/- 3% (Figure 3.7). 
 
Taken together, these observations indicate that sKATP, but not mKATP channels, 
are involved in the trigger mechanism of Nicorandil-induced preconditioning for 
late-phase protection of skeletal muscle against infarction. 
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Figure 3.7.  Role of sarcolemmal KATP (sKATP) and mitochondrial KATP (mKATP) 
channels in the trigger mechanism of Nicorandil-induced late phase 
preconditioning against I/R injury in porcine skeletal muscle. There were 4-5 
pigs with bilateral LD muscle flaps in each group. All LD muscle flaps were 
subjected to 4hr ischaemia and 48hr reperfusion. Intravenous administration of 
saline or saline containing Nicorandil (3 mg/kg) was performed 24hr before 4hr 
of sustained ischaemia (late phase protection). The sKATP channel inhibitor 
HMR-1098 (6 mg/kg), the mKATP channel inhibitor 5-HD (10 mg/kg) or the 
nonspecific KATP channel inhibitor Glib. (1 mg/kg) was injected intravenously at 
10 min before intravenous administration of saline or saline containing 
Nicorandil.  5-HD was also co-infused intravenously (5mg/kg) for 30min after 
bolus injection.  Muscle infarction was assessed after 48hr reperfusion.  Values 
are expressed as mean +/- SEM; n = 4-5 pigs.  Means with an asterisk are 
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similar and are significantly different from means without an asterisk (one-way 
ANOVA and Neuman-Keuls multiple range test; *p < 0.05). 
 
 
 
3.7 Study 6: To investigate the role of ATP-sensitive K+ (KATP) channels in 
the effector mechanism of Nicorandil-induced late IPC. 
 
Nicorandil (3mg/kg) was injected intravenously 24hr before subjecting LD 
muscle flaps to 4hr ischaemia and 48hr reperfusion. The selective mKATP 
channel inhibitor 5-HD was injected intravenously as a bolus 10min before the 
onset of the 4hr ischaemic insult.  This effectively blocked the late-phase 
preconditioning effect of Nicorandil, resulting in an infarction rate of 35.7 +/- 
3%, similar to the ischaemic control of 42.0 +/- 4% (Figure 3.8).   
 
Further to this, the non-specific KATP channel inhibitor Glibenclamide (1 mg/kg) 
was also injected as an intravenous bolus 10 minutes before the onset of 4hr 
ischaemia.  Glibenclamide also completely blocked the late-phase of infarct 
protection conferred by Nicorandil, resulting in an infarction rate of 42.8 +/- 1%, 
similar to the ischaemic control of 42.0 +/- 4% (Figure 3.8). 
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n = Control Nicorandil Nico. + 
5-HD 
Nico. + 
HMR 
Nico. + 
Gliben. 
5-HD HMR-
1098 
Gliben. 
1 40 23 20 44 45 40 27 46 
 35 17 31 49 46 45 33 40 
2 48 26 31 35 41 41 48 47 
 36 16 38 29 39 46 51 40 
3 36 27 26 27 42 43 49 40 
 29 28 32 30 43 46 42 43 
4 62 15 10   40 33 46 
 51 18 24   45 50 34 
5       49  
       55  
Mean 42.0 21.3 26.5 35.7 42.8 43.1 43.6 42.1 
SEM 3.8 1.9 3.1 3.6 1.1 0.9 3.0 1.6 
 
Table 3.12. The addition of pharmacological probes 5-HD, HMR-1098 and 
Glibenclamide 24 hr after Nicorandil pre-treatment, before ischaemia. Flap 
necrosis expressed as % infarction, mean and standard error of the mean (SEM), 
n = 3-5 pigs. 
 
 
On the other hand, the selective sKATP channel inhibitor HMR-1098, when given 
10min before the 4hr ischaemic insult, had no significant effect (26.5 +/- 3%), 
when compared to Nicorandil-induced late phase preconditioning (21.3 +/- 2%).  
Equivalent doses of HMR-1098, 5-HD and Glibenclamide were also injected 
24hr following sham saline injection and 10min before the onset of 4hr 
ischaemia and 48hr reperfusion.  This resulted in infarction rates of 43.6 +/- 3%, 
43.1 +/- 1% and 42.1 +/- 2% respectively, similar to the ischaemic control of 
42.0 +/- 4% (Figure 3.8).   
 
Taken together, these observations indicate that mKATP, but not sKATP channels, 
are involved in the mediator mechanism of Nicorandil-induced preconditioning 
for late phase protection of skeletal muscle against infarction. 
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Figure 3.8. Role of sarcolemmal KATP (sKATP) and mitochondrial KATP (mKATP) 
channels in the effector mechanism of Nicorandil-induced late phase 
preconditioning against I/R injury in porcine skeletal muscle. There were 3-5 
pigs with bilateral LD muscle flaps in each group.  All LD muscle flaps were 
subjected to 4hr ischaemia and 48hr reperfusion.  Nicorandil was injected at 
24hr prior to the onset of 4hr sustained ischaemia (late-phase preconditioning). 
The sKATP channel inhibitor HMR-1098 (6 mg/kg), the mKATP channel inhibitor 
5-HD (10 mg/kg) or the nonspecific KATP channel inhibitor Glibenclamide (1 
mg/kg) was injected intravenously 24hr after intravenous administration of 
saline or saline containing Nicorandil (3 mg/kg), 10 min before the onset of the 
4hr ischaemic insult and 48hr of reperfusion.  5-HD was also co-infused 
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intravenously (5mg/kg) for 30min after bolus injection. Muscle infarction was 
assessed after 48hr of reperfusion.  Values are expressed as mean +/- SEM; n = 
3-5 pigs. Means with an asterisk are similar and are significantly different from 
means without an asterisk (one-way ANOVA and Neuman-Keuls multiple range 
test; *p < 0.05). 
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4.0  DISCUSSION 
 
4.1  Choice of Porcine Model 
 
As stated earlier, the pig was chosen as the large animal model for our study due 
in part to the extensive research into its musculoskeletal anatomy and vascular 
territories of skin, fascia and muscle (Patterson et al. 1967; Milton 1972; Meyer 
et al. 1978; Prather et al. 1979; Millican et al. 1985). As well as this, our lab has 
prior experience in conducting experiments and in the perioperative care of these 
animals (Mounsey et al. 1992; Morris et al. 1993; Pang et al. 1995; Hopper et al. 
2000).  
 
The pig has been used as an experimental animal model in anatomical research 
for many years.  When compared to other potential large animals such as a 
canine or rabbit model, the pig is a tight-skinned mammal with almost identical 
tissue qualities to human skin, with the exception of the pannniculus carnosus.  
In the late 60’s Patterson et al (Patterson et al. 1967) demonstrated that despite 
the subtle differences in the anatomy of porcine skin, this thin muscular layer did 
not contribute to the blood supply of the skin.  Our interest in this model was 
regarding its skeletal muscle anatomy. Millican and Poole accurately described 
the reliable and consistent anatomy of the Latissimus Dorsi (LD) muscle, raised 
as a pedicled myocutaneous flap (Millican et al. 1985).  They further 
demonstrated a consistent thoracodorsal pedicle as the principle arterial supply 
with two accompanying venae comitantes and thoracodorsal nerve.  They also 
reported that perforators from underlying intercostal vessels supplied the caudal 
part of the LD muscle, a feature present in humans. 
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Several large landmark studies in myocardial preconditioning have been 
performed using a canine model (Murry et al. 1986; Auchampach et al. 1993; 
Mizumura et al. 1995; Hausenloy et al. 2009).  Further to this the canine LD 
muscle flap has been described for dynamic cardiomyoplasty in a canine chronic 
cardiac failure model (Soberman et al. 1990; Takemura et al. 1991).  However, 
several investigators have noted distal ischaemia of the pedicled LD muscles 
after transfer, and have therefore resorted to vascular delay to improve LD 
viability and function for cardiomyoplasty (Carroll et al. 1997; Carroll et al. 
1997).  The reason for the distal necrosis in canine pedicled LD flaps is due to 
their different vascular territories in relation to human LD muscle.  In particular, 
the pattern of branches between thoracodorsal and intercostal perforators differs 
between the dog and the human (Yang et al. 1999).  Therefore pedicled canine 
LD muscle flaps are not a good predictor of their human counterpart.  
 
We used castrated male Yorkshire pigs for our study with a mean animal weight 
of 17.9kg (range 15 – 24kg).  We realised that this size of animal would be 
required to give us a consistent magnitude of 13 x 8cm LD muscle flaps.  The 13 
x 8cm flap allowed us to standardise our results with previous studies using the 
porcine LD flap model, resulting in further validation.  In this weight range, 
animals were approximately 8 – 10 weeks of age and had not reached sexual 
maturity.  Despite this, castrated animals were used to reduce animal aggression 
and to prevent any hormonal influences on the study results.  It can be debated 
that as we have not used an ‘adult’ large animal model, there may be a potential 
effect on translational validity.    When comparing our mean animal weight to 
other porcine studies in myocardial ischaemic preconditioning, Bolli’s group 
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used pig models in two studies with mean weights of 25kg (Tang et al. 1996) and 
28kg (Qiu et al. 1997).  As well as this, Galie et al used 30 – 35kg pigs to study 
Nicorandil-induced myocardial protection (Galie et al. 1995).  The findings from 
these myocardial protection models have translated to subsequent human trials 
such as CESAR 2 (Patel et al. 1999) and IONA (2002), demonstrating the 
validity of an adolescent porcine model.  
 
It can be argued that a smaller animal model could have been used to simulate 
the ischaemia-reperfusion injury, such as the rat LD skeletal muscle flap model 
(Harralson et al. 2005).  However, there are species differences in these smaller 
animal models with their vascular anatomy and muscle morphology.  Firstly, 
there is a difference in the ratio of type 1 and 2 fibres in rat and pig skeletal 
muscle.  Specifically, skeletal muscles of small animals like the mouse and rat 
have a more substantial proportion of type 2B fast twitch fibres.  As body size 
increases, the 2B fibre population diminishes, producing a reversed ratio of type 
1 to type 2 fibres, present in larger animals like the pig and human (Sutherland et 
al. 2006).  Secondly, the LD muscle in humans and pigs has a Mathes & Nahai 
Type 5 blood supply (Mathes et al. 1981) where the muscle is supplied by a 
principle vascular pedicle and secondary segmental supply.  In the rat model the 
principle thoracodorsal pedicle is not sufficient to maintain a vascularised flap 
and the intercostal supply must therefore remain intact (Carroll et al. 1997; 
Harralson et al. 2005).  In the human and pig, the muscle can be reliably raised 
on the principle pedicle and our lab has shown the porcine LD muscle to remain 
viable on this pedicle for up to 48 hours in a sham control group (Pang et al. 
1995).  Further to this, the thoracodorsal pedicle in a 20kg animal is of a 
sufficient caliber to allow for repeated vascular clamping without fear of undue 
 115 
shearing forces and intimal damage.  Another concern in small animal models is 
the thickness / volume of the LD flap.  A thin flap may be able to obtain 
sufficient oxygenation and nutrition by direct diffusion from adjacent tissues, 
thereby with partial muscle survival independent of the vascular pedicular 
supply. 
 
A total of 9 animals were used in preliminary ‘pilot’ control studies, as well as a 
further 4 animals in model development for another study (McAllister et al. 
2008). There is a learning curve of surgical technique required to raise bilateral 
muscle flaps and skeletise the thoracodorsal vascular pedicle consistently to 
allow for reliable vessel clamping.  There were 4 premature animal deaths in our 
study.  1 animal died on the 1st postoperative day due to respiratory 
complications; 3 of the animals died or had to be euthanised intra-operatively 
due to metabolic acidosis / multi-organ failure.  The most likely explanation for 
the intra-operative deaths is a syndrome called malignant hyperthermia, which 
can be triggered in various pig breeds by stress or several volatile anaesthetic 
agents such as Halothane, Isoflurane and Enflurane (Rosenberg et al. 1994).  
This syndrome, also known as Porcine Stress Syndrome (PSS), has been 
associated with a genetic mutation present in 19% of the Yorkshire breed of pigs 
(O'Brien et al. 1993). 
 
 
4.2  The Bilateral LD Muscle Flap Model 
 
As stated earlier, the anatomy of the LD muscle flap in the pig model is 
remarkably similar to the human LD muscle.  Getty states that the LD muscle 
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takes origin from the lower 4 ribs and inserts together with teres major into the 
humerus.  The muscle lies superficially deep to the pannniculus carnosus and can 
be easily isolated on its principal thoracodorsal vascular pedicle, which remains 
superficial to the deep fascia (Getty 1975). 
 
There are a variety of muscles in the pig that could be used in a skeletal muscle 
flap model.  The rectus abdominis is a good-sized muscle with reliable vascular 
anatomy, however is technically a more challenging dissection taking a longer 
period of time (Boyd et al. 1990).  The gracilis muscle has been raised by 
Addison et al in a hindlimb remote IPC porcine model (Addison et al. 2003).  
However, due to the hind limb anatomy of the pig, this muscle is shorter and 
more triangular than in the human.  Further to this, the resultant scar and postop 
swelling on the inner aspect of the hindlimb may interfere with animal mobility 
after surgery. 
 
The LD muscle flap is a superficial flap with surface markings that are easy to 
palpate behind the forelimb shoulder.  The skin incisions are in such a place that 
they heal well with low risk of infection or dehiscence.  With an average 18kg 
animal, we were able to consistently raise bilateral 13 x 8cm LD muscle flaps, 
isolated on the thoracodorsal pedicle.  The musculotendinous humeral insertion 
was left intact but ligated to insure only a single blood supply remained.  The 
muscles can be elevated and denervated without affecting the animal’s forelimb 
locomotion.  All muscles were raised through standardised trap-door skin 
incisions on the flanks. 
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We decided not to involve a microvascular anastomosis of the thoracodorsal 
vessels in our muscle flap model.  We realise that effectively, we are using a 
pedicled muscle flap model to validate ischaemic preconditioning in free muscle 
transfer.  To ensure there were no neurogenic influences, the motor nerve to LD 
was transected, however it can be argued that there are microscopic sympathetic 
nerves adherent to the pedicular vessels which will not be divided.  This was 
addressed by Addison et al who showed that intravenous injection of the 
ganglionic blocker Hexanthonium prior to preconditioning failed to block the 
preconditioning effect of remote IPC (Addison et al. 2003).  Therefore, we 
believe that there are no neurogenic influences in our model and it is 
representative of a model for free tissue transfer. 
 
The porcine LD muscle flap model has been extensively employed and validated 
in our lab (Mounsey et al. 1992; Pang et al. 1995; Pang et al. 1997; Hopper et al. 
2000).  We raised a standard 8 x 13cm LD flap, which has been used in the 
previous studies performed with this muscle flap model.  We subjected our flaps 
to a standardised 4-hour ischaemic interval, which produced an infarct rate of 40 
+/- 2%.  This infarction rate compares to previously published results using a 4-
hour ischaemic interval: 38 +/- 6% (McAllister et al. 2008); 46 +/- 2% (Moses et 
al. 2005); 44 +/- 4% (Addison et al. 2003).  
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4.3  The dose-response effect of Nicorandil-induced late phase infarct 
protection 
 
Nicorandil was given as an intravenous bolus + 60 minute infusion 24 hours 
before the onset of the 4 hour ischaemic insult followed by 48 hours of 
reperfusion.  When deciding on which incremental doses to use, we were guided 
by previous large animal studies.  Tang et al (Tang et al. 2004) gave a similar i.v. 
bolus + 60 minute infusion to conscious rabbits, with a total concentration of 1.9 
mg/kg.  Mizumuru et al, in a canine myocardial infarct model, used a dose of 
0.85 mg/kg given over 75 minutes and a dose of 2 mg/kg given over 190 minutes 
(Mizumura et al. 1995; 1996).  Galie et al used an intravenous infusion of 
Nicorandil with a range of dosage from 1.6 to 3.6 mg/kg in a porcine myocardial 
infarct model (Galie et al. 1995).  Verdouw et al also employed a range of 
dosage from 0.15 to 1.5 mg/kg over an infusion period of 10 minutes in a 
porcine myocardial model (Verdouw et al. 1987).  Finally, Lamping et al 
(Lamping et al. 1984) used an i.v. bolus + 140 minute infusion in a canine 
myocardial model, giving a total Nicorandil concentration of 3.6 mg/kg. 
 
We therefore chose a range of incremental concentrations of Nicorandil (0.1 
mg/kg to 3 mg/kg), delivered by an initial i.v. bolus followed by a 60 minute 
infusion. 24 hours later, the LD muscle flaps were subjected to 4 hours global 
ischaemia followed by 48 hours reperfusion. After 48 hours reperfusion, muscle 
infarction was assessed by the nitroblue tetrazolium reduction technique. 
 
At dosages of 0.1 – 0.3 mg/kg Nicorandil, there was only partial protection 
conferred against I / R injury with a reduction in percentage muscle infarction 
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from 42% to 32%.  Further increasing the dose to a range of 1 - 2 mg/kg resulted 
in a minimal further reduction in muscle infarction to 27%.  Once the Nicorandil 
concentration was increased to 3 mg/kg, we achieved a more stable response rate 
with a reliable reduction in muscle infarction with a mean of 22%.  Despite the 
significant reduction in infarction achieved with a Nicorandil concentration of 1-
2 mg/kg, we found a rather inconsistent range of results with these dosage 
parameters.  It was therefore decided to use the optimal concentration of 3 mg/kg 
for our experiments. 
 
Taken together these results demonstrate that with incremental i.v. Nicorandil 
concentration, increasing reduction in the percentage muscle infarction was seen, 
when compared to the ischaemic control.  Several animals were injected with 
Nicorandil concentrations of 4-5 mg/kg, however no further reductions in the 
infarction were seen and not enough numbers were performed to include in our 
charted results. 
 
 
4.4  The effect of intravenous Nicorandil on mean arterial blood 
pressure (MAP) in the porcine model 
 
The measurement of mean arterial pressure (MAP) was performed over a period 
of 90 minutes on anaesthetised animals.  Our results have shown that a dose of 3 
mg/kg i.v. Nicorandil resulted in a significant reduction in MAP over a period of 
60 minutes, but the MAP normalised once the Nicorandil infusion has ceased 
(Figure 3.2). 
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This larger dose of Nicorandil was similar to that used by Lamping et al in their 
canine myocardial model (Lamping et al. 1984).  The infarct reduction induced 
by Nicorandil was also accompanied by a 25 – 30 mmHg reduction in MAP in 
Lamping’s study.  Mizumura et al surmised that the beneficial effect on infarct 
size could be due to its peripheral haemodynamic effect as opposed to a direct 
action on the KATP channels (Mizumura et al. 1995).  That may be true in the 
case of acute phase ischaemic preconditioning, as in Lamping’s study.  However, 
in our study, a hypotensive dose of i.v. Nicorandil was given 24 hours before the 
onset of our ischaemic insult.  Markham et al (Markham et al. 2000) reviewed 
the pharmacokinetics of the drug and stated that “a single dose of intravenous 
Nicorandil is almost entirely eliminated from plasma within 8 hours”.  They 
further reported that the half-life of this rapid phase of elimination was 
approximately 45 minutes.  These findings correspond to our blood pressure data 
showing a rapid normalisation of MAP after completing the i.v. infusion.  
Further to this, Verdouw et al demonstrated in a porcine model, that Nicorandil 
exerted a pronounced effect on preload (venous dilatation) and afterload 
(systemic arterial dilatation) even at lower concentrations.  They also performed 
regional haemodynamic studies using the radioactive microsphere technique and 
demonstrated that even at the higher concentrations of Nicorandil, there was no 
significant increase in regional blood flow to skeletal muscle (Verdouw et al. 
1987). 
 
One potential limitation of our methodology, which may have influenced the 
MAP data, is regarding the device used to measure blood pressure.  The 
polyethylene cannula (Becton Dickinson, Franklin Lakes, NJ, USA) that was 
used, was too wide bore to cannulate any peripheral arteries, therefore the 
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femoral artery was used.  This meant an exploratory incision and dissection of 
the vessel to allow ligation and placement of the cannula.  This required 
induction of general anaesthesia and intubation of the animal prior to MAP 
measurement.  A pentobarbital infusion was used, as described earlier in the 
methodology.  Pentobarbital sodium was used as maintenance anaesthesia during 
the flap-raising surgery due to it’s non-hypotensive effects, however this 
preservation of blood pressure during anaesthesia is due to an increase in 
systemic vascular resistance as shown by Thomson et al (Thomson et al. 1991).  
In the presence of a potent nitrate vasodilator like Nicorandil, inhibiting systemic 
vascular resistance reduces afterload.   Therefore pentobarbital anaesthesia may 
in fact contribute to the hypotensive effects seen during Nicorandil infusion.  To 
combat this issue the lab has recently upgraded the apparatus to allow dorsal ear 
arterial cannulation and monitoring under ketamine sedation.  Unpublished 
findings more recently have demonstrated higher resting / control MAP, as well 
as a less pronounced reduction in MAP.  Further work is required to substantiate 
these observations. 
 
 
 
4.5  The Efficacy of Nicorandil in Induction of Late Phase IPC of 
Porcine Skeletal Muscle 
 
This is the first report on the efficacy and time course of pharmacological late 
phase IPC to protect skeletal muscle from I/R injury.  Intravenous Nicorandil (3 
mg/kg) given 24 hr before the onset of a 4 hr ischaemic insult followed by 48 hr 
reperfusion, results in a significant reduction in skeletal muscle infarction from 
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40 +/- 2% (ischaemic control) to 22 +/- 2%.   This equates to a 45% reduction in 
muscle necrosis.  This is comparable to the efficacy of remote ischaemic 
preconditioning, where instigation of 3 cycles of 10 minute occlusion / 
reperfusion in the hind limb of a pig induced a late phase of protection with a 
40% reduction in the muscle necrosis (Moses et al. 2005).  Further to this, the 
efficacy of Nicorandil-induced late IPC is comparable to acute / classical IPC.  
Pang et al demonstrated a 44% reduction in infarct size after acute 
preconditioning of porcine LD muscles with 3 cycles of 10 minutes occlusion / 
reperfusion (Pang et al. 1995). 
 
The efficacy of Nicorandil-induced late phase IPC has been demonstrated in 
other species.  Iliodromitis et al demonstrated that an oral dose of Nicorandil 
recaptured the waning effect of acute IPC in a rabbit myocardial infarct model, 
however they were unable to show that Nicorandil initiated IPC by itself 
(Iliodromitis et al. 2003).  Bolli’s group, in their rabbit myocardial infarct model, 
also demonstrated the efficacy of Nicorandil-induced late phase IPC.  Using an 
i.v. bolus + 60 minute infusion of Nicorandil 24 hours before the ischaemic 
insult, they showed a 54% reduction in myocardial infarct size compared to the 
ischaemic control (Tang et al. 2004). 
 
Since the advent of Nicorandil as a potent pharmacological preconditioning 
agent against myocardial ischaemia, researchers have investigated its potential to 
protect other solid organs from ischaemia reperfusion injury. More recently Suto 
et al demonstrated Nicorandil-induced protection of small intestine from I/R 
injury (Suto et al. 2011).  Shimizu and colleagues reported that I/R injury of rat 
kidney was ameliorated by Nicorandil (Shimizu et al. 2011). Further to this, 
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Yamazaki et al demonstrated the effectiveness of i.v. Nicorandil in providing 
protection of hepatic tissue from subsequent ischaemic injury (Yamazaki et al. 
2011).   
 
 
4.6  The Time Course of Nicorandil in Induction of Late Phase IPC of   
Porcine Skeletal Muscle 
 
We clearly demonstrated a biphasic response in infarct reduction instigated by 
Nicorandil injection.  Nicorandil induced an acute phase of IPC, which lasted for 
4-6 hours before waning.  A second window of protection appeared 12-24 hours 
following Nicorandil injection, which was as robust as the acute phase and was 
maintained for a period of 48 hours before disappearing (Figure 3).  This is the 
first study to report the entire biphasic time course of Nicorandil-induced IPC, 
showing the initial waning period at 4-6 hours, followed by the disappearance of 
the preconditioning effect after 72 hours post injection.  This is also the first 
report of Nicorandil-induced late IPC in skeletal muscle. 
 
Nicorandil-induced late IPC has been studied before in Bolli’s rabbit myocardial 
infarct model.  They reported a significant reduction in myocardial infarct size 
with a single i.v. dose of Nicorandil, given 24 hours before the ischaemic insult.  
However, they only reported on a single time-point of 24 hours for late phase 
IPC (Tang et al. 2004).  There have been several earlier studies published on 
pharmacological late phase IPC of skeletal muscle.  Interestingly, Wang et al 
triggered late-phase IPC in rat cremaster muscle with sodium nitroprusside (a 
donor of nitric oxide) (Wang et al. 2000).  Maldonado’s lab published two 
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studies demonstrating the efficacy and time-course of late-phase IPC in rat LD 
muscle models (Quan et al. 2004; Harralson et al. 2005).  They corroborate our 
evidence that the duration of late-phase protection lasts from 24 to 72 hours 
before ischaemia, but disappears at 96 hours (Harralson et al. 2005).  However, 
this late IPC stimulus was elicited mechanically and is demonstrated in a 
devolved animal model with inherent differences in skeletal muscle anatomy and 
morphology as has been discussed earlier. 
 
 
4.7  Mechanism of Nicorandil-Induced Late Phase IPC of Porcine 
Skeletal Muscle 
 
Late-phase preconditioning with a single intravenous dose of Nicorandil 24 
hours before the onset of ischaemia resulted in a significant reduction of 
mitochondrial free calcium (m[Ca2+]), preservation of muscle ATP content and a 
reduction in myeloperoxidase activity during the 1st hour of reperfusion, when 
compared with the ischaemic control levels.  This is the first in-vivo study to 
demonstrate a reduction in m[Ca2+] secondary to Nicorandil-induced IPC. 
 
These findings agree with previous work in our lab by Moses et al.  They 
induced late-phase IPC by noninvasive remote IPC using a hindlimb tourniquet.  
Muscle biopsies were taken at similar ischaemic and reperfusion time-points 
from the dorsal edge of the LD muscle flap.  They also reported that late-phase 
IPC is associated with preservation of muscle ATP content and a significant 
reduction of neutrophilic myeloperoxidase activity in the first 90 min of 
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reperfusion (Moses et al. 2005; Moses et al. 2005).  However, they did not 
measure m[Ca2+]. 
 
 
4.7.1 Mitochondrial Free Calcium Content 
 
We chose to measure the mitochondrial free calcium content (m[Ca2+]) because 
of its central role in the mechanism of mitochondrial calcium overload leading to 
cell necrosis. Ca2+ is primarily transported into mitochondria via uniporters, once 
the cytosolic Ca2+ concentration rises to a certain threshold. Ca2+ equilibration in 
the mitochondria is brought about by mitochondrial Na+ / Ca2+ exchangers that 
pump Ca2+ back into the cytoplasm.  During oxidative stress conditions, i.e. 
reperfusion injury, these cation exchangers can reverse resulting in Ca2+ 
transport back into the mitochondria (Ermak et al. 2002).   
 
The potassium ion (K+) is the most important cation regulator of mitochondrial 
activity.  As stated earlier, mitochondria have K+ impermeable membranes and 
therefore rely on bidirectional K+ cycling via K+ / H+ antiporters (K+ efflux) and 
ATP-sensitive K+ channels (K+ entry).  Opening of KATP channels in skeletal 
muscle cells during an ischaemic insult, results in a shortening of the myocyte 
action potential, which leads to a reduction of cellular Ca2+ influx and ultimately 
prevention of cytosolic Ca2+ overload. 
 
Nicorandil is a potent KATP channel opener, which has been shown in our study 
to induce a late phase of IPC resulting in infarct protection associated with a 
significant reduction in m[Ca2+]  during the first hour of reperfusion.  Nicorandil-
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induced activation of KATP channels leading to prevention of m[Ca2+] overload 
has been demonstrated in several models of isolated cardio-myocytes 
(Holmuhamedov et al. 1999; Ishida et al. 2004).  However to date there are no 
in-vivo animal studies that have demonstrated this link. 
 
 
4.7.2 Muscle ATP Content 
 
We have reported here that preconditioning with i.v. Nicorandil, results in a 
significant preservation of skeletal muscle ATP content during the first hour of 
reperfusion.  This is in keeping with previous studies in our lab demonstrating an 
increase in ATP content during reperfusion, following late remote IPC (Moses et 
al. 2005), early remote IPC (Addison et al. 2003) and early local IPC (Pang et al. 
1995). 
 
Other investigators have demonstrated a similar preservation of muscle ATP 
content in the myocardium of the dog (Murry et al. 1990), rabbit (Janier et al. 
1994; Takaoka et al. 1999) and rat (Kobara et al. 1996).  In contrast, there is a 
scarcity of papers demonstrating this finding in Nicorandil preconditioning.  
Early investigations of Nicorandil by Garrett Gross’ lab reported preservation of 
endocardial ATP and total adenine nucleotides in Nicorandil-induced acute 
preconditioning in a canine myocardial model (Pieper et al. 1987).  This finding 
was later corroborated by Murakami et al in a pig I/R model, where Nicorandil 
pretreatment preserved energy metabolism in the sub-endocardium by increasing 
ATP (Murakami et al. 2002). 
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There is still debate regarding the mechanism by which IPC preserves total 
muscle ATP content.  Murry and colleagues propose that this increase in ATP 
content is due to a reduction in myocardial energy demand during ischaemia, as 
well as a reduced rate of ATP consumption (Murry et al. 1990).  Janier et al 
concluded that IPC enhanced glucose uptake and anaerobic glycolytic 
production of ATP (Janier et al. 1994).  Vuorinen et al (Vuorinen et al. 1995) 
indicated that it was in fact the inhibition of the enzyme mitochondrial ATP 
synthase activity that leads to sparing of ATP in the reperfusion period.  This 
hypothesis has since been disproved by Vander Heide et al (Vander Heide et al. 
1996) and Bosetti et al (Bosetti et al. 2000), who state that there is no difference 
in mitochondrial ATP synthase levels between IPC and ischaemic controls. 
 
 
4.7.3 Neutrophilic Myeloperoxidase Activity 
 
We have demonstrated in this study that levels of neutrophilic myeloperoxidase 
(MPO) activity did not change during the 4-hour ischaemic insult in both 
ischaemic control and Nicorandil pre-treated animals.  However, during the first 
hour of reperfusion there was a significant reduction in the rise of MPO activity 
in the Nicorandil pre-treated group compared to the control group.  This is in 
keeping with previous studies in our lab where late remote IPC (Moses et al. 
2005), early remote IPC (Addison et al. 2003) and early local IPC (Pang et al. 
1997) significantly attenuated MPO activity during early reperfusion of porcine 
skeletal muscle. 
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It has been well documented that neutrophil accumulation occurs during early 
reperfusion. Several myocardial models have demonstrated that reduction of 
myocardial I/R injury by classical IPC is associated with a reduction in 
neutrophilic myeloperoxidase accumulation during early reperfusion (Mizumura 
et al. 1995; Wang et al. 1999).  Further to this, Nicorandil-induced 
preconditioning of the myocardium in the dog (Mizumura et al. 1995) and pig 
(Galie et al. 1995) model has reported that the infarct protection is associated 
with a reduction in myeloperoxidase accumulation during reperfusion. 
 
Despite these findings there is still much controversy regarding the role of 
neutrophils in I/R injury. Neutrophils are known to generate Reactive Oxygen 
Species (ROS), which can result in tissue injury, and so are seen causally in the 
development of I/R injury.  On the other hand, neutrophil accumulation is seen 
simply as an inflammatory response to myocyte necrosis.  This is supported by 
evidence indicating that I/R injury occurs in neutrophil-free systems, such as 
buffer-perfused rabbit hearts (Liu et al. 1992) and isolated ventricular myocytes 
(Maddaford et al. 1999).  Further to this Vanden Hoek et al (Vanden Hoek et al. 
1997) were able to generate ROS during the ischaemic insult to isolated 
cardiomyocytes. 
 
 
4.8   Pathways of Nicorandil-Induced Late Phase IPC of Porcine Skeletal   
Muscle 
 
The phenomenon of IPC is a complex multifactorial pathway, occurring in 
various species, in a number of tissue types.  Researchers have targeted several 
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of the upstream ‘triggers’ of IPC, such as the Adenosine receptor (Auchampach 
et al. 1993; Baxter et al. 1994; Addison et al. 2003), opioid receptor (Addison et 
al. 2003), as well as the signal transduction pathway involving Protein Kinase C 
(Hopper et al. 2000; Uchiyama et al. 2003).  These different triggering and 
mediator mechanisms converge on a downstream end-effector pathway resulting 
in activation of ATP-sensitive potassium (KATP) channels, prevention of 
mitochondrial calcium overload and preservation of muscle ATP content. 
 
We decided to investigate this end-effector pathway of KATP activation and its 
involvement in Nicorandil-induced late-phase IPC of skeletal muscle.  The 
involvement of KATP channels in late-phase IPC was identified by Mei et al in a 
canine myocardial model (Mei et al. 1996), and by Bernardo et al (Bernardo et 
al. 1999) in a rabbit model.  This involvement was also discovered to translate to 
skeletal muscle by Moses et al (Moses et al. 2005) in the porcine LD muscle flap 
model. 
 
 
4.8.1 Role of the sarcolemmal KATP channel (sKATP) 
 
We have demonstrated, with the results of Study 5, that sKATP, but not mKATP 
channels, are involved in the trigger mechanism of Nicorandil-induced late phase 
IPC of porcine LD muscle flaps.  Specifically, the selective sKATP channel 
inhibitor HMR-1098 abolished the preconditioning effect of Nicorandil, when 
given 24 hours before the onset of a 4-hour ischaemic insult followed by 48 
hours reperfusion.  The non-specific KATP channel inhibitor Glibenclamide was 
also effective in blocking the preconditioning effect of Nicorandil, when given 
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24 hours before the onset of the 4-hour ischaemic insult.  Further to this, the 
selective mKATP channel inhibitor 5-HD was ineffective when given before 
Nicorandil injection, 24 hours before the onset of the ischaemic insult. 
 
This result compares with previous findings in the porcine skeletal muscle 
model, where it was observed that sKATP channels were involved in the trigger 
mechanism of hindlimb remote IPC for late-phase protection of skeletal muscle 
against infarction (Moses et al. 2005).  Our results in skeletal muscle corroborate 
those in the myocardium where Patel et al demonstrated that the sKATP channel 
was required as a trigger but not a mediator for delayed cardioprotection in the 
rat heart, elicited by mechanical late IPC (Patel et al. 2005) and opioid-induced 
late IPC (Patel et al. 2002).   Further to this Gross et al found that the sKATP 
channel blocker HMR-1098 was able to block delayed cardioprotection elicited 
by Diazoxide (KATP agonist) (Gross et al. 2003). However, this goes against the 
findings of Takashi et al (Takashi et al. 1999), who reported in a rat myocardial 
infarct model, that activation of mKATP channels triggered late-phase 
preconditioning, although they did not look at sKATP channel function in this 
regard. 
 
The activation of sKATP channels and their role in acute IPC is unclear.  In 
Nicorandil-induced acute IPC, Sato demonstrated involvement of mKATP but not 
sKATP channels (Sato et al. 2000), whereas it was confirmed that both mKATP and 
sKATP are involved in the acute-phase cardioprotection afforded by Diazoxide 
(Tanno et al. 2001) and Nicorandil (Tsuchida et al. 2002).  These complex 
findings can be summarised by stating that there is evidence in several species 
and tissues to implicate the involvement of sarcolemmal KATP channels in the 
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trigger mechanism of delayed IPC.  The role of sKATP channels in acute IPC is 
less clear and probably involves both sKATP and mKATP channels. 
 
 
4.8.2 Role of the mitochondrial KATP channel (mKATP) 
 
In study 6 we reported that mKATP channels, but not sKATP channels, are 
involved in the mediator mechanism of Nicorandil-induced late phase IPC of 
porcine skeletal muscle flaps. Intravenous injection of the selective mKATP 
inhibitor 5-HD or the non-selective mKATP inhibitor Glibenclamide 10min before 
the onset of 4 hours ischaemia abolished the late-phase preconditioning effect of 
Nicorandil.  In contrast, the selective sKATP inhibitor HMR-1098 failed to block 
the late preconditioning effect of Nicorandil when given directly before the 4-
hour ischaemic insult. 
 
This again compares to the results by Moses et al, where it was reported that 
mKATP channels were involved in the effector mechanism of hindlimb remote 
IPC for late-phase protection of skeletal muscle against infarction (Moses et al. 
2005). 
 
The evidence for mKATP channels as a mediator / end-effector in late-phase IPC 
is fairly unanimous.  Bernardo (Bernardo et al. 1999) and Mullenheim 
(Mullenheim et al. 2001) both reported, in the rabbit model, that late-phase 
cardioprotection was abolished by the non-selective KATP blocker Glibenclamide 
as well as the selective KATP blocker 5-HD, thereby implicating the mKATP 
channel as a mediator in late IPC.  This was further corroborated by Mei and 
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colleagues, who reported that both Glibenclamide and 5-HD inhibited 
pharmacologically induced late-phase IPC in the canine myocardial model (Mei 
et al. 1996).  
 
As stated earlier, Nicorandil is a hybrid clinically licensed drug, acting as a nitric 
oxide donor and KATP channel opener.  There is certainly some controversy 
regarding the role of Nitric Oxide (NO) in the late phase of preconditioning.  
Bolli’s group have stated in several papers that NO is pivotal in the initiation and 
mediator pathways of late phase of IPC in the conscious rabbit myocardial model 
(Qiu et al. 1997; Takano et al. 1998).  Further to this, Wang et al reported that 
NO initiated late-phase infarct protection in rat skeletal muscle (Wang et al. 
2000) and murine myocardium (Wang et al. 2005). 
 
On the other hand, when Nicorandil elicits its infarct reduction effect, Mizumura 
et al reported mediation by KATP channels and not by NO (Mizumura et al. 
1996).  Furthermore, Post et al confirmed that NO is not involved in classical 
(acute) IPC of porcine myocardium (Post et al. 2000).  However, to date there 
are no studies examining the role of KATP channels in Nicorandil-induced late 
IPC.  Tang et al demonstrated Nicorandil-induced late phase IPC in conscious 
rabbits, however they did not look at the role of KATP channels (Tang et al. 
2004).  In isolated myocyte preparations, Nicorandil acts directly to open mKATP 
channels (Sato et al. 2000) which in turn attenuates mitochondrial Ca2+ overload 
(Ishida et al. 2004).  In addition to this, we have shown that the non-selective 
KATP channel inhibitor Glibenclamide completely abolished the Nicorandil-
induced infarct protective effect, when given before Nicorandil or before 
ischaemia, returning the infarction rate to a level comparable with the ischaemic 
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control.  One hypothesis is that the nitrate-type effects of Nicorandil may serve 
to potentiate the KATP channel activation, rather than operate independently, as 
eluded to in the ventricular myocyte model of Sasaki et al (Sasaki et al. 2000).  
This would suggest Nicorandil’s main mechanism of action in late-phase IPC is 
by activation of KATP channels. 
 
 
 
4.9   Conclusion 
 
In surgical specialties such as Plastic, Orthopaedic and Vascular surgery, a 
muscle or groups of muscles are placed under ischaemic conditions, either 
through tourniquet or vascular clamp control.  Further to this, autogenous free 
muscle transfer is used routinely in plastic surgery to reconstruct form and/or 
function.  Human skeletal muscle is known to have a critical ischaemia time of 
approximately 2.5 hours, however functionality of muscle contraction may be 
affected well before this time.  Protracted operations with long tourniquet times, 
as well as unpredictable complications such as thrombosis and vasospasm can 
prolong this ischaemic interval leading to irreversible muscle necrosis. 
 
The phenomenon of IPC has evolved from the localised invasive cyclical 
clamping of blood vessels, to remote IPC with a hind-limb tourniquet.  With the 
advent of pharmacomimetic drugs, we are now able to elicit infarct protection 
with a systemic single dose in myocardial as well as skeletal muscle.   
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This is the first study to demonstrate the efficacy of late-phase IPC with 
intravenous Nicorandil, to provide 48 hours of uninterrupted infarct protection 
from ischaemia / reperfusion injury in skeletal muscle.  Specifically, 
pharmacological preconditioning by Nicorandil was biphasic with an acute phase 
that appeared when intravenous injection of Nicorandil was given immediately 
and up to 4-6 hours before the ischaemic insult.  This acute phase of 
preconditioning waned; and then a second / late phase of protection appeared at 
12-24 hours following Nicorandil injection and lasted for a period of 48 hours 
before disappearing.  This late phase of protection was as robust as the acute 
phase, producing a 45% reduction in the amount of muscle necrosis, compared to 
ischaemic controls.  
 
As well as producing an equally robust reduction in muscle necrosis, we 
demonstrated that late phase pharmacological preconditioning by Nicorandil 
reduced the amount of mitochondrial Ca2+ overload during early reperfusion.   
Nicorandil pre-treatment was also responsible for attenuating neutrophil 
infiltration during early reperfusion, as seen by a significant reduction in 
myeloperoxidase activity. We further demonstrated that Nicorandil 
preconditioning reduced the rate of ATP depletion in the myocyte during early 
reperfusion injury, with a significant preservation of muscle ATP content, 
compared to the ischaemic control. 
 
Pharmacological probes were employed to delineate the molecular mechanism of 
Nicorandil preconditioning.  The selective sarcolemmal KATP (sKATP) channel 
inhibitor HMR-1098 abolished the preconditioning effect when given before 
Nicorandil injection, but had no effect when given 24 hours later, before the 
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ischaemic insult.  In addition, the selective mitochondrial KATP channel inhibitor 
5-HD abolished the preconditioning effect when given before the 4-hour 
ischaemic insult but had no effect when given 24 hours earlier, before Nicorandil 
injection.  Taken together these findings demonstrate that sarcolemmal KATP 
channels are involved in the trigger mechanism, and mitochondrial KATP 
channels in the mediator mechanism of Nicorandil-induced late phase IPC of 
skeletal muscle.   
 
The additional use of the non-selective KATP inhibitor Glibenclamide abolished 
the preconditioning effect when given before Nicorandil pretreatment or before 
ischaemia.  These findings infer that the late-phase preconditioning effect is 
primarily by the KATP channel-opening effect of Nicorandil and not by its nitrate 
donor properties.  However, to confirm these findings, further study is required 
using pharmacological probes to block the nitrate effects of Nicorandil during 
the triggering mechanism. 
 
With the establishment of the molecular mechanism of early and late phase 
pharmacological preconditioning by Nicorandil, it is hoped that further studies 
can be designed to look at the reliability of Nicorandil as a pharmacological 
preconditioning agent for patients undergoing elective free muscle transfer in 
reconstructive surgery. 
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5.0  PERSPECTIVES & LIMITATIONS 
 
With the discovery of Nicorandil as a potent KATP channel opener, we have 
demonstrated the potential use of a clinical drug in elective global 
preconditioning of skeletal muscle prior to elective reconstructive, vascular or 
musculoskeletal surgery.  Not only can Nicorandil trigger an immediate infarct-
protective effect, it can transmute skeletal myocytes to an ischaemia-tolerant 
phenotype.  This infarct protection can last for a period of 48 hours, which is the 
crucial post-operative window in autogenous free muscle transfer, with regard to 
anastomotic complications such as vasospasm and pedicle thrombosis. 
 
Since the advent of the first human hand transplant in 1998, the field of 
composite tissue allotransplantation (CTA) has been advancing exponentially.  
Ischaemia Reperfusion (I/R) injury has been shown to contribute to acute 
rejection in animal allotransplant models (Pradka et al. 2009).  Further to this, a 
clear link has also been demonstrated between prolonged ischaemia time and 
long-term graft survival in solid organ transplantation (Opelz et al. 1994).  
Several strategies have been investigated to prevent I/R injury in solid organ 
transplantation, such as the induction of heat shock proteins and the use of 
cooled preservation solutions like ‘University of Wisconsin’ solution (Caterson 
et al. 2013).  However there is very little evidence of successful intervention 
strategies to reduce I/R injury in CTA. 
 
CTA is more technically and logistically challenging than autogenous free tissue 
transfer and this is reflected by the prolonged ischaemia times.  Hand 
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transplantation cases average 6 hour ischaemia times (Petruzzo et al. 2011) and 
face transplantation approximately 4 hours (Pomahac et al. 2012). 
 
Baumeister et al used the intervention of heat stress preconditioning to 
upregulate heat shock protein 72 (HSP-72), demonstrating a reduction in I/R 
injury of hind limb allotransplants in a rat model (Baumeister et al. 2004).  
Further to this, Villamaria et al recently validated a porcine CTA model using 
allogeneic gracilis myocutaneous flaps (Villamaria et al. 2012).  It would 
therefore be feasible to examine the impact of Nicorandil preconditioning in a 
porcine microvascular CTA model.  This could lead to the discovery of an 
exciting new therapeutic intervention against I/R injury in solid organ and 
composite tissue allotransplantation. 
 
A perceived limitation of this study was the use of Nicorandil in the intravenous 
form.  The majority of studies have also looked at the efficacy of intravenous 
Nicorandil, given by a bolus + infusion.  This has the risk of exposing the animal 
to the vasoactive effects of the drug, resulting in reduced vascular resistance and 
ultimately a fall in mean arterial pressure.  Interestingly, Iliodromitis et al studied 
the efficacy of oral Nicorandil in a rabbit myocardial model.  They gave an oral 
dose of 5 mg/kg for 5 consecutive days prior to ischaemic insult, reporting a 
preservation of the IPC effect, which waned after 4-6 hr in the ischaemic control.  
However, this cannot be concluded as true late-phase IPC as the interval was 
only 90 minutes, and the oral Nicorandil by itself was insufficient to initiate IPC 
(Iliodromitis et al. 2003).   
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Despite this, the efficacy of oral Nicorandil in human clinical trials, such as the 
‘Impact of Nicorandil in Angina’ (IONA) study (2002) and the CESAR 2 trial 
(Patel et al. 1999), has demonstrated the myocardial protective effect of this drug 
when chronic oral dosing is employed.  Further to this, Qi et al demonstrated that 
oral dosing with up to 30 mg/kg Nicorandil enhanced the survival of ischaemic 
skin flaps in a rat model (Qi et al. 2006).  This effect was probably due, in part, 
to a direct nitrate vasodilator effect on the cutaneous vascular plexuses.  
Nicorandil’s effect may have also been due to its anti-apoptotic action on 
endothelial cells.  This has been confirmed in-vitro by Date et al where it was 
found that Nicorandil could inhibit apoptosis of endothelial cells by activation of 
mitochondrial KATP channels (Date et al. 2005). 
 
The bioavailability of Nicorandil in the oral format is >75%.  Peak plasma 
concentrations of the drug occur 0.5 to 1 hour after administration and steady 
state dosing can be achieved within 4 days (Markham et al. 2000).  This suggests 
a novel application for this drug, where a repeated oral dose could be 
administered to provide a chronic level of infarct protection for a dedicated post-
operative period.  Oral Nicorandil could provide infarct protection for 
autogenous free muscle, myocutaneous and fasciocutaneous flap transfer.  As 
well as this, our findings may lead to further work looking at Nicorandil-induced 
late-phase preconditioning of solid organs against I/R injury.  They could have 
huge therapeutic potential in transplant surgery.  There is already evidence that 
Nicorandil acutely protects intestine (Suto et al. 2011), kidney (Shimizu et al. 
2011) and liver (Yamazaki et al. 2011) from I/R injury.  More studies need to be 
designed to look at the effects of chronic oral Nicorandil dosing in providing a 
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robust continuous period of infarct protection during the prolonged ischaemia of 
organ transplant surgery. 
 
Another limitation of this project was the measured endpoint of myocyte 
necrosis in the LD muscle flaps of the pig.  The amount of cell necrosis was 
quantified using the well-validated Nitroblue tetrazolium reduction technique, 
followed by computer planimetry to map out the areas of necrosis and give an 
overall percentage muscle infarction rate.  This method has been well validated 
in our lab with the porcine LD flap model (Addison et al. 2003; Moses et al. 
2005; Moses et al. 2005; McAllister et al. 2008), as well as in other animal 
models (Labbe et al. 1988; Qiu et al. 1997).  However, is there a more sensitive 
measure of permanent myocyte dysfunction, rather than eventual cell necrosis? 
 
We know that the critical ischaemic limit of skeletal muscle is approximately 2.5 
hours, after which point reperfusion-induced irreversible tissue necrosis occurs 
(Sjostrom et al. 1982).  However, less is known about the effect reperfusion 
injury has on contractility.  Gurke et al was able to demonstrate that 3 cycles of 
ischaemic preconditioning resulted in an improvement in muscle endurance and 
contractility of post-ischaemic extensor digitorum longus muscle in a rodent 
model (Gurke et al. 1996; Gurke et al. 2000).  Further to this, McLaughlin et al 
employed a similar method using the rat cremaster skeletal muscle model to 
show that treatment with the endogenous amino acid taurine, protected 
electrophysiological function in skeletal muscle against ischaemia reperfusion 
injury (McLaughlin et al. 2000). 
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‘Myocardial stunning’ is the term given to abnormalities in systolic or diastolic 
contractile function of cardiomyocytes exposed to a period of ischaemia.  
Investigators have targeted this phenomenon, demonstrating the involvement of 
reactive oxygen species (ROS) and transient cytosolic calcium overload during 
the early phase of reperfusion (Bolli 1990; 1991).  As we have seen throughout 
this discussion, the mechanisms of acute and late ischaemic preconditioning 
translate from myocardial to skeletal muscle animal models.  Interestingly, late 
phase preconditioning has been shown to protect against myocardial stunning in 
the rabbit model (Bolli et al. 1997) but not in the pig  (Qiu et al. 1997). 
 
Although KATP channels are central to infarct protection, they do not appear to be 
involved in amelioration of myocardial stunning (Takano et al. 2000).  
Paradoxically, it appears that Nitric Oxide is more central to the reduction of 
myocardial stunning (Bolli et al. 1997; Bolli et al. 1997; Takano et al. 1998).  
However, there are few studies looking at the impact of Nicorandil on 
myocardial stunning.  Iwamoto et al looked at Nicorandil’s KATP opening and 
nitrate properties in the rabbit myocardial model and concluded that KATP 
channel opening was central to the protection of the myocardium from stunning 
but could not exclude a role for NO during reperfusion (Iwamoto et al. 1993).   
 
The effects of Nicorandil on skeletal muscle contractile function have never been 
looked at and could highlight a therapeutic potential in optimising free muscle 
flaps for functional muscle transfer in the treatment of disorders such as facial 
palsy and Volkmann’s ischaemic contracture. 
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